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PREFACE 
The Centre has undertaken operational research studies to evolve methodologies 
suitable for application in the National Tuberculosis Programme for improving its 
efficiency. The areas covered under this research programme are case finding and 
case-holding, two important components for improving the Programme. Towards this 
objective, different strategies to suit the local conditions are being tried. The op- 
erational research study in an urban set up (Madurai) utilising the NSS volunteers 
indicates that the case-finding efficiency could be substantially improved; however, 
with regard to case-holding, more inputs are needed to ensure better drug compliance. 
Hence, necessary steps are being taken to modify the procedures to ensure better drug 
compliance by patients. The study in a tribal area with inadequate medical facilities 
in the district of North Arcot Ambedkar, utilises literate youths for case finding and 
health education activities. If this strategy is found successful, it may be adopted in 
other tribal areas in the country and could be extended to other health programmes 
also. 
Short Course Chemotherapy regimens of 6- month duration with split- dose double- 
drug combination administered on alternate days during an initial intensive phase of 
2 or 3 months appear to be promising and could be as efficacious as when the four 
drugs are administered together on thrice- weekly basis. The interim findings of the 
study have shown similar sputum conversion rates at the end of 2 months of treatment 
necessary to confirm their efficacies. The success of the splid-dose double-drug combi- 
nation therapy could lead to dispensation of these combinations in blister-packs and 
enable better supervision, ensure better acceptability of treatment and greater chances 
of reducing adverse reactions, all of which are aimed at successful completion of treat- 
ment without compromising on the efficacy of treatment. Long-term follow-up results 
of a trial with a fully oral 8-month daily regimen containing ethambutol have revealed 
the benefit of the drug in overcoming initial drug resistance to isoniazid. Encouraged 
by the results of our short course chemotherapy studies in various forms of extrapul- 
monary tuberculosis, a pilot study on cutaneous tuberculosis with an SCC regimen 
was started to standardise diagnostic criteria and to study the feasibility. 
in sputum positive pulmonary tuberculosis patients. However, long-term follow-up is 
Fiberoptic bronchoscopic studies are being explored to evolve a bacteriologically 
confirmative test of diagnosis for pulmonary tuberculosis in adults and in children. 
Pulmonary physiology studies to assess the lung functions in pulmonary tuberculosis 
patients, which could eventually help to explain the respiratory crippling in relation 
to the gradation and duration of illness will be undertaken. 
A bacteriological study in pulmonary tuberculosis patients to elucidate the princi- 
ples of chemotherapy with the split double-drug combination of anti-tuberculous drugs 
has been completed. In vitro studies were conducted and reported, while in vivo stud- 
ies in experimental tuberculosis in mice are in progress. A study on the occurrence 
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of mycobacteria in the environment in the Tiruvallur BCG Trial area indicated the 
predominance of two species of mycobacteria, namely, M.Fortuitum and MAIS com- 
plex. This study will lead to a better understanding of the hypothesis of immuno 
modulation brought about by the non-tuberculous mycobacteria in individuals vacci- 
nated with BCG. Studies of Beta lactamase activity in M.tuberculosis are in progress. 
Search is being continued for newer drugs for the treatment of patients with drug re- 
sistant bacilli and for possible reduction of duration of chemotherapy. In this context, 
some derivatives of fluoro quinolones have been screened for their antimycobacterial 
activity in vitro and the results have been reported. Bioluminescence assays have been 
standardised for rapid screening of drug susceptibility in mycobacteria, especially in 
non-cultivable M.leprae. This will be a useful tool in the assessment of progress during 
treatment of multi-bacillary forms of leprosy. Further, this method of assay avoids 
using radio-labelled substances which are expensive and hazardous. 
Pharmacological investigations relating to drug interaction with the commonly used 
anti-tuberculosis drugs in short course chemotherapy are being carried out. This is an 
off-shoot of the ongoing controlled clinical study with split double-drug combination 
of anti-tuberculosis drugs. Furthermore, the study will elucidate the effectiveness of 
combined formulations of the drugs. 
Development of immuno-diagnostics is one of the frontier areas of research of the 
Centre. Accordingly, search is continuing for highly specific antigens and antibodies for 
early detection of pulmonary and extra pulmonary forms of tuberculosis. Efforts are 
also being made to develop DNA probes for diagnosis of mycobacterial infections. The 
technique of RFLP has been applied in epidemiological studies of South Indian isolates 
of M.tuberculosis and also in the study of isolates of M.tuberculosis from patients who 
had a relapse after favourable response to treatment. The latter study may help to 
distinguish between relapses and reinfection among patients treated successfully with 
bactericidal and sterilising regimens of short course chemotherapy. T-cell cloning tech- 
nology has been established and will enable study of cytokines derived by the clones in 
response to specific antigenic stimulation in addition to the understanding of the role 
of T-cell subsets in the immunology of tuberculosis. 
Studies of seroprevalence of HIV infection among tuberculosis patients and tuber- 
culosis among HIV infected individuals are being continued to enable understanding of 
the dual infection. These studies are very important since there is a global awareness 
vi 
of tuberculosis emerging as a major health problem in the years to come in the wake 
of an upsurge in HIV infection. 
Valuable contributions are being made in the epidemiology of tuberculosis by the 
conduct of studies to evolve surveillance methodology and diagnosis of childhood tu- 
bercuolsis at field level on a community basis. The interim findings of the prospective 
long-term follow-up study being carried out to find out the fate of sputum positive 
patients treated under DTP may have far reaching implications. 
During the year, significant improvements have been introduced in the library and 
information services at our Centre. A fortnightly publication 'Tuberculosis Alert' 
has been started. Facilities have been made for literature search and library resource 
sharing. Several library activities have been computerised. 
The long felt need for a good animal house facility is going to be fulfilled as the 
construction of the building is taking shape rapidly. The building will house rabbits, 
guinea pigs and mice. This facility will be very useful in experiments for develop- 
ing reliable immuno diagnostics, detailed pharmacological investigations with anti-TB 
drugs, screening of newer anti TB drugs and for development of vaccinee in addition 
to basic research with mycobacteria 
The basic, applied and operatianal research studies conducted at this Centre are 
aimed at improving the efficiency of the National Tuberculosis Programme. The en- 
vironment conducive for research, provided by the adminstartive and other infras- 
tructure facilities being utilised by the Scientists of this Centre to turn out high 
quality research. The fact that a number of young and bright scholars are attracted 
every year by the Centre to pursue doctoral programmes bears testimony to the quality 
of guidance. Often, these programmes form part of the research activities of the Centre. 
The Scientific Advisory Committee, which met on the 26th October 1992 under 
the Chairmanship of Dr.S.P.Tripathy, Director General, ICMR gave valuable guidance 
and helpful suggestions regarding the research activities of the Centre. 
Finally, I wish to place on record my deep appreciation and grateful acknowl- 
edgement for the unstinted support received by me from my colleagues and for their 
untiring efforts which has enabled the Centre to make useful and significant research 
contribution in tuberculosis. 
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OPERATIONAL RESEARCH STUDIES - COMPLETED 
Short course chemotherapy under District Tuberculosis Programme 
(Completed study, 1983-92) 
Short course chemotherapy was introduced in 18 districts spread over 10 states in 
India during the period March 1983 to March 1985. The Centre had been given the 
responsibility of implementation and monitoring of the programme. Periodic analysis 
is undertaken based on the returns received from these districts, and the data presented 
in each year's annual report (1983 onwards). 
The Scientific Advisory Committee decided, in 1991, that the monitoring of the 
programme in far away districts should be transferred to National Tuberculosis Insti- 
tute and that the Centre should confine its activities to four nearby districts to carry 
out its operational research studies in addition to monitoring. Accordingly, the Centre 
stopped its monitoring activity in 14 of the 18 districts in 1992. This report given a 
brief review of the main findings in the 18 districts. 
The regimens prescribed were: 
1. 2RHZ2/4RH2: Rifampicin 600 mg plus isoniazid 600 mg plus pyrazi- 
namide 2.0g given twice a week for 2 months, followed by rifampicin 600 
mg plus isoniazid 600 mg twice a week for the next 4 months, all doses 
2. 2RHZ/6TH: Rifampicin 450 mg plus isoniazid 300 mg plus pyrazinamide 
1.5g daily for 2 months, followed by thioacetazone 150 mg plus isoniazid 300 
mg daily for the next 6 months, the drugs being collected by the patients 
once in 15 days for self administration. 
being administered under supervision in the clinic. 
3. 2RHZ/4RH2: Rifampicin 450 mg plus isoniazid 300 mg plus pyrazi- 
namide 1.5g daily for 2 months, followed by rifampicin 600 mg plus isoni- 
azid 600 mg twice a week for 4 months; in the first two month, the drugs 
are collected once in 15 days for self- administration, and in the next 4 
months, all doses are administered under supervision in the clinic 
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Three policies of treatment, one each for 6 districts, are followed: 
Policy A: Regimen 1, with regimen 2 as an alternative. 
Policy B: Regimen 2. 
Policy C: Regimen 3, with regimen 2 as an alternative. 
Sputum positive pulmonary tuberculosis patients aged 15 years or more are eligible 
to be treated with short course chemotherapy, provided they have not received more 
than 2 months of previous specific chemotherapy for tuberculosis. 
The programme of short course chemotherapy is integrated with the District Tu- 
berculosis Programme; hence, implementation and running of the programme is the 
responsibility of the staff of the District Tuberculosis Centres and the PHIS (Periph- 
eral Health Institutions). The Centre’s staff made periodic monitoring visits to the 
districts. 
Sputum examination and intake to SCC: The average sputum examination 
per month from the inception of SCC ranged from 740 to 3616 in the Policy A districts, 
622 to 2289 in the Policy B districts and 589 to 1612 in the Policy C districts; the 
percentage of positivity ranged from 4.2% to 13.6%, 7.2% to 9.6% and 4.5% to 9.1% 
respectively. The percentage of eligible patients started on SCC ranged from 46% - 
82% in the Policy A districts, 31% - 74% in the Policy B districts and 42% - 80% in 
the Policy C districts. 
Detailed analysis on smear positivity in the districts over the years have shown that 
there was variation in some districts, but there was no clear-cut trend. Since the study 
was terminated in June 1992, this report covers the period January to June 1992 only. 
Considering all the 18 districts, the smear positivity in 1992 (January to June) was 
less than 5% in one district, 5 %- 9% in 10 districts and 10% - 15% in the remaining 
7 districts. 
As for the intake to SCC, in 1992, 80% or more of eligible patients were put on 
SCC in 4 districts, 70% - 79% in 2, 60% - 69%,in 3, 50% - 59% in 2 and less than 50% 
in 7. 
Contribution of PHIs to case finding: The total number of sputum examina- 
tions at the DTC during 1992 (see Table 1) ranged from 1018 to 4267 in the Policy 
A districts (median 1793), 424 to 3355 in the Policy B districts (median 1189) and 
940 to 3815 in the Policy C districts (median 1894). The corresponding figures for 
the PHIs are 660 to 19624 (median 6111), 1253 to 14253 (median 4240), and 2009 to 
10508 (median 5694), respectively. The sputum positive cases diagnosed at the DTC 
ranged from 142 to 726 (median 301) in the Policy A districts, 128 to 352 (median 212) 
in the Policy B districts and 165 to 402 (median 314) in the Policy C districts. The 
corresponding figures for the PHIS are 65 to 1646 (median 540), 148 to 1316 (median 
218) and 60 to 790 (median 186) respectively. The over-all positivity rate at the DTCs 
is 14.6% and at the PHIs, 6.3%. The PHIs examined 16 sputum specimens for every 
10 
positive obtained whereas at the DTCs, it was 7 specimens for every positive. Of the 
total 12846 sputum positive cases diagnosed during the period January to June, 1992, 
59% were diagnosed at the PHIs and 41% at the DTCs. 
Table 1 
Percentage of sputum positives at DTC and PHIs 
Data on contribution of PHIs to case finding from 1985 to 1991 are given in Table 
2. Intensive monitoring of DTP was initiated by TRC in 1988. The PHI contribution 
to case finding has increased from an average of 50% during 1985- 88 to an average of 
57% during 1989-91. 
Treatment completion rate: From the inception of SCC, treatment completion 
rates for 8 different cohort periods (ending June, 1992) are available. In the current 
cohart(Ju1y 91 to June 92), the SCC treatment completion rate is 50% and ranges from 
41 to 61% in the Policy A districts, 69% and 33 to 78% in the Policy B districts and 
61% and 42 to 72% in the Policy C districts. Considering the treatment completion 
rate during the entire 8 cohort periods, 53% (median 56%) of patients in Policy A 
districts, 58% (median 54%) in Policy B districts and 56% (median 56%) in Policy C 
districts had received 80% or more of chemotherapy. 
Considering the treatment completion rate according to the regimen during the 8th 
cohort period (July 1991 to June 1992), 44% of 1038 patients on the fully supervised 
regimen had received 80% or more of chemotherapy, compared with 64% of 8858 pa- 
tients on the unsupervised regimen and 56% of 983 patients on the partially supervised 
regimen. The treatment completion rates for the previous 7 cohort periods were 49% 
of 4129, 53% of 1719, 47% of 1716, 46% of 1351, 51% of 1446, 50% of 1478 and 50% 
of 1186 patients for regimen 1, 48% of 2834, 50% of 4598, 57% of 6509, 54% of 5601, 
55% of 6985, 54% of 10062 and 60% of 10026 patients for regimen 2 and 76% of 631, 
11 
(Jan - Jun 1992) 
55% of 1258, 63% of 1043, 60% of 1051, 61% of 1325, 55% of 1215 and 64% of 907 
patients for regimen 3. Thus the completion rate remained more or less the same over 
the years with regimens 1 and 2; there are wide variations in the rates with regimen 3 
but there is no clear-cut trend. The treatment completion rates for the entire 8 cohort 
periods were 49% for regimen 1, 56% for regimen 2 and 60% for regimen 3. 
Treatment completion rates for SCC and standard regimens are available for 5 
concurrent cohort periods. Results of the last two concurrent cohorts for the period 
July 89 to June 91 are given in Table 3 and the results of previous three cohorts were 
provided in the 1991 annual report. The treatment completion rate with SCC for the 
5 cohort periods has been consistent for Policy A and B districts, the medians being 
51%, 54%, 55%,53% and 50% in Policy A districts and 52%, 48%, 50%, 52% and 56% 
for Policy B districts. In Policy C districts, the median treatment completion rate 
has gone up from 52% and 51% in the 1st and 2nd cohort periods to 60%, 56% and 
65% in the 3rd, 4th and 5th cohort periods respectively. Considering the standard 
chemotherapy data for all the 18 districts, the median treatment completion rate had 
improved from 27% in the 1st cohort period to 36% in the 2nd, 39% in the 3rd, 34% 
in the 4th and 38% in the 5th cohort period. 
Table 2 
PHI contribution1 
Percentages of initial sputum examinations and sputum positives 
I 
1. Based on 16 districts only, for North Arcot and Anrangabad, separate figures 
for DTC and PHI were not reported from 1985 to 1988. 
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Table 3 
Concurrent cohorts - SCC vs standard (STD) 
(period 7/89 to 6/91) 
1.Month/Year 
This study, therefore, demonstrates that short course chemotherapy can be intro- 
duced in DTP provided adequate infrastructure is available in districts and the mean 
treatment completion rates of five cohorts (1986 to 1991) were 55% and 41% with SCC 
and standard regimens respectively. Similarly, case finding can also be improved by 
intensive monitoring at PHI level. 
***** 
Utilisation of NSS volunteers to augment the components of a City TB 
Programme 
(Completed study, 1990-92) 
Details regarding rationale, aims, area of study, personnel involved in this pilot 
study along with some findings were given in our two previous annual reports. This 
report gives a brief review of all the activities of the National Service Scheme (NSS) 
volunteers. 
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Sensitisation methods adopted and cases detected : During the period 
December 1990-July 1992, four camps were held in Madurai and different strategies 
were adopted for educating the public to get their cooperation. In addition to student 
volunteers, other agencies also were utilized for sensitising the population. In the first 
two camps, students did a door to door enumeration, detected the chest symptomatics 
and motivated them to attend the camps. In the 3rd and 4th camps, the students 
enacted street plays only. Main sensitisation methods by other agencies consisted of 
announcements through All India Radio (AIR), public announcements with the use 
of microphone and wall posters in the area. The wall posters were descriptive of 
the features of chest symptomatics and gave details about date and time of camps, 
etc. These wall posters were seen or read by the local community. Table 1 gives 
the population covered and the symptomatics who attended these camps and sputum 
positives detected. 
Table 1 
Sensitization methods adopted 
and the cases detected in the four camps 
Area covered 
Population 
sensitization 
methods 
(a) by students 
(b)other agencies 
No.of persons 
registered 
Symptomatics 
Sputum specimens 
collected1 
Smear positives 
I (Dec 90) 
Aruldaspuram 
25,000 
Enumeration 
Film shows and 
hand bills 
380 
288 
412 
21 
Camp 
II (Feb 91) 
Sellur 
18,000 
Enumeration & 
street plays 
Wall posters 
and public 
announcements 
359 
330 
466 
15 
III (Sep 91) 
Aruldaspuram 
and Sellur 
43,000 
Street plays 
Wall posters 
and AIR anno 
uncements 
237 
233 
316 
17 
Aruldaspuram 
and Sellur 
43,000 
Street plays 
Wall posters 
263 
209 
327 
6 
1.More than one sputum specimen was collected from each symptomatic, if necessary. 
The chest symptomatics attending the camps were questioned regarding the fac- 
tors which made them to attend the camp. This was done from the second camp 
onwards. The replies to the questions were analysed and are shown in Table 2. In 
the second camp, among all factors that were used to sensitise the community, enu- 
meratian contributed 40%, wall posters 29% and on their own 25%. In the 3rd camp, 
enumeration was not repeated and other strategies were tried. Among them, 42% of 
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symptomatics replied that the wall poster was the main motivating factor for them to 
attend. All India Radio announcements contributed 16% and neighbours, who came 
to know through these sources motivated 37% of the symptomatics. In the fourth 
camp, wall posters accounted 54%, street plays 10% and neighbours 35% for the at- 
tendance of chest symptomatics. Over all, sensitisation through wall posters, in the 
absence of door to door enumeration, is found to be the best among the strategies tried. 
Source of information 
Symptomatics who attended 
Camp II Camp III Camp IV 
No. % No. % No. % 
Enumeration 
Wall posters 
Street plays 
Mike announcements 
AIR announcements 
On their own 
Neighbour 
Total 
143 40 
103 29 
21 6 
3 1 
89 25 
359 101 
- - 
- - 
- - - - 
99 42 143 54 
12 5 27 10 
39 16 21 
- - - - 
87 37 91 35 
237 100 263 100 
- - - - 
Case-finding activity and regimens used: Case finding activity was carried 
out routinely in the two health facilities during the periods between the camps, in 
addition to cases detected during the camps. As a result, 93 sputum positives and 
38 x-ray positives were started on treatment during the period. Smear positives were 
started on SCC regimen (2EHRZ7/6EH7). The drug collection was fortnightly in first 
phase and monthly in the second phase. X-ray positives were given a 12 month regimen 
(TH or EH) with monthly collections. 
Case-holding : Once a patient is started on treatment, student volunteers were 
asked to visit them twice a month, irrespective of the regularity of drug collection. 
Students during their visits motivated the patients to take drugs regularly and did 
pill counting and recorded visit details in a form. Table 3 gives the visit pattern of 
students during 1991. Of the total 410 visits made, 25% and 22% of the visits were 
done in August and September. Less than 5% of the visits were done in March, April, 
June, November and December. The months with low percentage of visits correspond 
to their examination and vacation periods. Students could visit only during evening 
and were able to meet the patients only on 165 (40%) of the occasions. 
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Table 2 
Source of information leading the symptomatics 
to attend the camp 
1. includes visits made to smear-negative but x-ray positive patients. 
Table 4 gives the frequency of visits (in 1991) to patients home for 57 patients. A 
total of 14% of the patients were not visited at all due to reasons like out of area, lack 
of proper address, early migration, death etc. A minimum of 1 to 3 visits were done 
in 18%, 4 to 6 in 26%, 7 to 9 in 23% and 10 or more in 19% of the patients. On an 
average, each patient was visited 5.8 times. 
Table 5 describes the results in the cohort of patients admitted till the end of 
December 1991. Of 83 patients admitted, 43% collected 75% or more of prescribed 
drugs, 63% collected 50% or more of drugs and 28% of patients collected less than 25% 
of drugs prescribed. It is observed that the student force could not contribute to any 
improvement in case-holding in spite of several visits they made to contact each patient. 
It is therefore concluded that NSS volunteers may not be useful for case-holding which 
happens to be the most important component in the programme, but they can play 
a significant role in sensitising the community, particularly when intensive campaigns 
can be carried out for short periods. 
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However, since only the girl students were involved in this investigation, it is in- 
tended to undertake another investigation in which only the male students would be 
involved. 
***** 
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1. Patients admitted upto the end of December, 1991. 
OPERATIONAL RESEARCH STUDIES - IN PROGRESS 
Pilot study in Jawadhu hills for augmentation of District Tuberculosis Pro- 
gramme among tribals 
(Ongoing study, 1990-96) 
As mentioned in 1991 annual report, a pilot study was undertaken in 19 roadside 
hamlets in a tribal area (Jawadhu hills). The aim was to find out the feasibility of 
utilising the services of literate youths and the ooran (leader) from each hamlet for 
identification of chest symptomatics in the community, proper collection of sputum 
from them, drug distribution to sputum positive patients and documentation of drug 
supply. The results have shown that literate youths were able to identify the chest 
symptomatics in the community but were not useful in supplying antituberculous drugs 
to the patients. 
It was decided to extend this study to 3 sub-centres of Jamnamarudur PHC in 
stages. These 3 sub-centres cover both interior and roadside hamlets. Study was 
started in September 1992. 
The Design of the Study is briefly described below : 
1. The Para Medical Workers (PMW) of the Centre will contact and identify one 
or more literate youths in each hamlet, who would be willing to participate in 
the District Tuberculosis Programme. The services of the literate youths will be 
utilised for census enumeration of the households of their villages, identification 
of chest symptomatics in the community, collection of sputum specimens from 
them and transportation of sputum specimens to the PHC. There is a proposal 
to pay honorarium to the literate youths. 
2. Required training and health education will be imparted to oorans and the liter- 
ate youths by Centre's staff. Health education includes basic aspects of diagnosis, 
treatment and methods for prevention of tuberculosis. 
3. Census books with necessary work instructions (in Tamil) filed in them will be 
given to the literate youths. 
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4. Each literate youth will be supplied with a pocket book for writing the names of 
chest symptomatics identified by him. 
5. The Centre’s study team will visit PHC once a month and stay there for about 
a week. The literate youths will be in advance informed about the dates of the 
visit. The literate youths collect the sputum specimens from symptomatica one 
day earlier to the team’s visit and bring the specimens to PHC on the next day 
to hand them over to the study team. 
The sputum smears will be examined by the laboratory technician at the PHC 
and also at Centre’s laboratory for confirmation. Culture examinations will be 
done only at our Centre. 
6. Chest symptomatics identified by literate youths will be interviewed by PMW/ 
Medical Officer(MO)/SociaI Worker(SW) to check whether they are true symp- 
tomatics or not. 
7. PMW/SW will visit, once in 3 or 4 months, a few hamlets and select some 
households, at random, and identify the symptomatics in those households to 
ensure that chest symptomatics have not been missed by the literate youths. If 
new symptomatics are found, PMW/SW will collect one sputum specimen from 
each new symptomatic. 
8. All sputum positive patients will be started on 2HRZ7/6TH and treatment will 
be initiated by MO/Village Health Nurse(VHN). The VHN will issue drugs once 
in 15 days to the patients and instruct them to take the drugs every day at night 
after food. She will also explain to the patient about the proper way of disposal 
of sputum. 
9. PMW/MO/SW will visit once a month, at random, each patient under treatment 
and do pill count to know whether the patient is taking the drugs regularly or not. 
This visit is also made use of to find out whether any side effects are encountered 
by the patient. 
Work carried out in the field from September 92 to December 92: Sixteen 
villages in one sub-centre (Athipattu) were covered. A total of 2426 persons were 
enumerated in 819 households and screened by the literate youths. Of 2426 persons, 
1485 were aged 15 years and above. 
To ascertain whether literate youths had identified all the chest symptomatics in 
the community, a 10% random sample of the eligible population and all the chest 
symptomatics identified by literate youths were interviewed by PMW/MO. The results 
are shown in Table 1. 
The literate youths had identified 116 (8%) chest symptomatica in 1485 persons 
(eligible population). The sputum specimens were collected from each of the 115 
persons and examined by smear and culture. Five specimens were positive by smear 
and two by culture only. 
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Table 1 
Evaluation of identification of symptomatics 
Cheat symptoms 
assessed by 
PMW/MO 
Chest symptoms assessed 
by literate youths 
Present Absent Total 
Present 115 10 125 
Absent 11 141 142 
Total 116 151 267 
Chemotherapy : Six of 7 positive patients were prescribed Rifampicin 450 mg 
plus isoniazid 300 mg plus pyrazinamide 1.5g daily for 2 months followed by thioaceta- 
zone 150 mg plus isoniazid 300 mg for a further period of 6 months. One patient in one 
village was started on 2HRZ2/4RH2 as he was willing for supervised chemotherapy. 
The study is in progress. 
***** 
Feasibility of utilisation of village Dais in improving DTP - A pilot study 
(Ongoing study, 1989-94) 
‘Dais’ are traditional birth attendants, conducting deliveries at home in the villages. 
Primary Health Centres in Tamil Nadu are conducting annual training courses for 
the village Dais, to teach them to conduct deliveries in a proper way under aseptic 
conditions. A pilot study was undertaken in Sriperumbudur taluk to explore the 
feasibility of utilising the services of Dais tor the improvement of case finding and case 
holding in the District Tuberculosis Programme. 
There are 44 villages with a population of 26413, divided into 12 clusters in Sripe- 
rumbudur taluk, Chingleput district, Tamil nadu. A voluntary health organisation 
(‘Prepare’) functioning in Sriperumbudur taluk, trains Dais to provide primary health 
care to the village community. The Dais supply drugs for minor ailments; their work 
is closely supervised by Community Health Assistants (CHAs) employed by ‘Prepare’, 
who work like Government-employed multi-purpose workers. 
In order to study the operational aspects of primary health care provided to the 
community through Dais, a health visitor and a clinic nurse from the Centre visited 13 
villages in Sriperumbudur area. The Dais in these villages were given practical training 
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by literate youths 
1. This person was a chest symptomatic but symptoms disappeared a the time 
of interview by PMW 
in identifying chest symptomatics and in collecting sputum specimens from them, for 
transportation to the Centre. Five such training programmes were organised in all. 
Case finding by village Dais : A total of 463 sputum specimens were collected 
from symptomatics identified so far and examined by smear for AFB and by culture 
for M.tuberculosis (see Table 1). Of these specimens, 57 (12%) were found to be 
positive by smear for AFB and 12 (3%) were negative by smear but positive by culture 
for M.tuberculosis. 
Chemotherapy : All patients positive by smear or culture were prescribed etham- 
butol 800 mg plus isoniazid 300 mg daily for 12 months. Treatment was initiated by a 
Medical Officer of the Centre, and monthly supplies of drugs were issued to the Com- 
munity Health Assistants, to be handed over to the respective Dais, who supplied the 
drugs to the patients with instruction to take the drugs at 'night after food. 
Table 1 
Case finding activity by village Dais 
Population catered by Dais 
(1991 census) 
Population aged > 15 years 
Total symptomatics identified 
Sputum positives 
by Dais and sputum examined 
by smear alone 
by smear and culture 
by culture alone 
over-all positivity 
- 
No. 
26413 
16740 
463 
36 } 57 
12 
69 
% 
63 
3 
12 
3 
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Out of 69 patients who were positive by smear or culture, 3 died before starting 
treatment. One patient refused chemotherapy in spite of repeated motivation (by TRC 
Medical Officer, Health Visitor and 'Prepare' Medical Officer), 1 patient belonged to 
an area outside the taluk, and 1 patient could not be identified. Treatment was initi- 
ated for the remaining 63 patients. During treatment, 6 patients died and 2 patients 
migrated. Two patients complained of giddiness after taking treatment in the first 
month of treatment but with reassurarnce felt better and the other refused to bake 
treatment inspite of repeated motivation. 
So far, 42 patients have completed one year of treatment. At the end of treatment, 
sputum was collected from 30 patients by the Dais. 
A Health Visitor does surprise drug check at least once a month for all patients 
on treatment. Efforts are also being made to identify and collect sputum samples 
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from chest symptomatics missed by Dais, by visiting a sample of households from 
each village where treatment is initiated for sputum smear-positive patients, and also 
interview a sample of chest symptomatics identified by the Dais whose sputum smear 
was negative. 
Attempts are being made to study how far Dais living in villages outside ‘Prepare’ 
area can be utilised for the improvement of DTP. 
***** 
Patient-to-patient motivation - An additional effort to improve compliance 
(Ongoing study, 199143) 
In 1990, a pilot study to investigate the feasibility of patient-to-patient motivation, 
by utilising a patient who has been regular for treatment to talk to a new patient, was 
initiated. As the study progressed, more treated patients were trained and after ensur- 
ing that they could motivate without difficulties, a controlled study was started in 1991. 
Only those patients who were found unsuitable for admission into our ongoing con- 
trolled clinical trial are admitted into this investigation. All the patients are treated 
with a 6-month fully supervised regimen with twice-weekly attendance. Half the pa- 
tients are allocated, randomly, to routine motivation and the other half to patient-to- 
patient motivation. 
Routine motivation (RM): Motivation by clinic staff only. 
Patient-to-patient motivation (PM) : Motivation by treated patients, in ad- 
dition to clinic staff motivation. Patient motivation is done on admission and at 1 and 
4 months. 
As compliance is likely to be influenced by, the distance to be travelled to reach 
the clinic, previous treatment and personal habits like drinking, stratified allocation 
procedures have been adopted. The Medical Officers, Clinic Nurses and Health Visi- 
tors are not informed about the group to which the patient is allocated. 
Defaulter action is similar for both groups, as prescribed in the DTP manual, i.e. 
a letter is posted on the day following the default and again on the 8th day. No home 
visits are made. Patients defaulting continuously for a month are considered “lost” . 
So far, 210 patients have been admitted in the study and 142 have completed 6 
months period of treatment. Sufficiently large number of patients would be completing 
6 months period of treatment in 1993 and the effect of the patient-to-patient motivation 
will be presented next year. 
The study is in progress. 
***** 
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CLINICAL STUDIES - COMPLETED 
Five-year follow-up of children treated for tuberculous meningitis with 
short course chemotherapy 
(Completed study, 1982-92) 
The five-year follow-up of patients admitted to short course chemotherapy study 
on tuberculous meningitis in children was completed this year. The detailed findings 
on the response to SCC were presented in 1988 annual report. In brief, patients 
aged between 1 and 12 years were randomly allocated, after stratification according to 
clinical severity, in equal proportion to the following 2 regimens. 
Regimen I : 2S7H7E7R3Z3/7R2H2: Streptomycin, isoniazid and ethambutol 
daily with rifampicin and pyrazinamide thrice a week for 2 months, followed by ri- 
fampicin and isoniazid twice a week for 7 months. 
Regimen II: 2S7H7E7R2Z2/7R2H2: Streptomycin, isoniazid and ethambutol 
daily with rifampicin and pyrazinamide twice a week for 2 months, followed by ri- 
fampicin and isoniazid twice a week for 7 months. 
In addition, the patients received non-specific therapy in the form of I.V. fluids, 
anti-oedema measures, anti-convulsants, and vitamins; as a policy, all received steroids 
for a period of 6-12 weeks. 
In all, 215 patients were admitted to the 2 regimens (107 to regimen I, 108 to 
regimen II). Of these, 1 died of a non-tuberculous cause and 29 patients were dis- 
charged against medical advice before completing therapy. The response to the al- 
located regimen could not be assessed in 35 patients, as their treatment had been 
modified because of the development of hepatitis or ocular changes. The analysis of 
response to treatment was therefore based on 150 patients. Of these, 40 (27%) patients 
died of tuberculous meningitis, 52 (35%) had neurological sequelae and 58 (39%) had 
complete recovery. The response was similar in the two regimens. 
The survivors at the end of treatment were followed up to find out the relapse 
rates and the course of the lesions. They were seen once a month up to 24 months, 
once in 3 months up to 36 months and once in 6 months up to 60 months. The 
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follow-up investigations included (a) a complete physical examination with special 
reference to the central nervous system, (b) a chest radiograph at 3-monthly intervals 
for patients who had persistent abnormality at the end of treatment, till they became 
normal and (c) cerebro-spinal fluid (CSF) examination for cell count, biochemical 
for patients with abnormal CSF findings at the end of treatment. In addition, between 
48 and 60 months, the following investigations are done: (d) electro-encephalogram; 
evidence of calcification. 
characteristics and bacteriological examination for M.tubcrculosis every three month 
(e) psychometric evaluation; (f) hearing assessment and (g) radiograph of skull for 
Of the 110 survivors at the end of chemotherapy, 16 patients had a persistant 
abnormality in the chest radiograph. In 13 patients, it became normal (in 6 patients 
between 10-12 months, in 4 between 13-24 months, in 3 between 25-36 months). In 2 
patients, there were calcified lesions at 18 and 28 months, respectively. In 1 patient, 
there were bronchiectatic changes (as a sequelae) up to 60 month the patient was seen 
by the surgeons and no surgical intervention was suggested. None of the 16 patients 
had any clinical deterioration or CSF abnormality necessitating retreatment. 
Five patients had abnormal CSF fluid findings (high protein) at the end of chemother- 
apy. In 4 patients, the values became normal at 10,14,30 and 54 months, respectively. 
examination could not be repeated there after as the parents were not willing for a 
lumbar puncture. None of the patients had clinical deterioration and the CSF culture 
For the 5th patient, the CSF examination at 48th month was still abnormal and the 
was negative for M.tuberculosis in all. 
Of the 110 survivors at the end of 9 months, 11 died subsequently and the remaining 
99 patients (28 with moderate sequelae, 14 with mild sequelae urd 57 with complete 
recovery) have completed the 60th monthly examination, i.e., 51 months of follow-up 
after stopping treatment. Table 1 shows the status at 60 months compared to the 
status at 9 months. 
Of the 28 patients with moderate sequelae, in 26, the status remained me, 1 
patient improved to mild sequelae while 1 patient recovered completely. Of the 14 
patients with mild sequelae, in 2 patients, the status changed to moderate,sequelae 
(1 patient developed weakness of lower and upper limbs and the other developed sec- 
ondary epilepsy as a late sequelae), in 10 there was no change, while the remaining 2 
patients recovered completely. 
Of the 57 patients with complete recovery, in 4, the statua changed to moderate 
sequelae (all developed secondary epilepsy) and, in 3, to mild requelae, while in the 
remaining 50 the recovery was maintained. 
Only one patient, who had mild sequelae at the end of treatment, had a relapse 
istry was abnormal and M.tuberculosis (sensitive to all drugs) was grown in culture. 
Intensive therapy was restarted but the patient died in 31st month. 
with in 3 months with reappearance of clinical symptoms and signs.The CSF biochem- 
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1. Including one patient who had a relapse. 
2. 5 patients died between 10 and 24 months, 2 between 25 and 36 months and 1 
patient between 37 and 48 months. 
In summary, there were no drop outs during the five year follow-up; only one 
patient had a relapse and all the five patients who had severe sequelae at the end of 
chemotherapy died during the follow-up period. 
**** 
Pulmonary function studies in patients who had been treated for spinal 
tuberculosis 
(Completed study, 1982-92) 
Pulmonary function studies were carried out in patients with tuberculosis of the 
spine who had been treated with short-course regimens (see 1985-86 annual report). 
The treatment had consisted of rifampicin plus isoniazid daily, for either 6 months with 
radical resection of the spinal lesion with bone grafting or 6 or 9 months chemotherapy 
alone. Since these tests had not been undertaken on admission to treatment, compar- 
ative pretreatment values for the different groups are not available. However, since 
allocation of the patients to the three treatment groups were at random, it is highly 
likely that the three groups were similar in respect of pulmonary function on admission. 
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The aims of the pulmonary function study were to find out (a) whether the cor- 
rection of deformity by radical surgery makes a significant contribution to improved 
respiratory function, and (b) whether the presence of a lesion in the thoracic or thoraco- 
lumbar region of the spine compromises the respiratory function to a greater extent 
than a lesion in the lumbar region. The following pulmonary function tests were ecar- 
ried out at yearly intervals, using P.K.Morgan Transfer Test Model C: 
1. Forced Vital Capacity (FVC) 
2. Forced Expiratory Volume in 1 sec (FEVl) 
4. Maximum Voluntary Ventilation (MVV) 
3. (FEV1 x 100)/FVC 
In addition, electrocardiograms were recorded in each patient every year and the 
patients were followed up for 10 years. Of the 269 patients who had first year assess- 
ments, 221 were assessed in the 5th year and 153 in the 10th year. The mean valuer 
of the four pulmonary function parameters for 1st and 10th year in ambulatory (AMB 
6/9HR) and surgical (RAD 6HR) series are given in Table 1. It indicates that there is 
no improved pulmonary function in patients in surgical series compared with patients 
in ambulatory series. 
Mean changes in pulmonary function parameters from 1st to loth year are shown in 
Table 2. Similarly, lesions in thoracic or thoraco-lumbar region have not compromised 
pulmonary function compared to lesions in lumbar region. Further detailed analysis is 
being carried out. 
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Table 3 
Mean changes in pulmonary function parameters 
from 1st to 10th year according to region of lesion 
Controlled clinical trial of dapsone as continuation chemotherapy beyond 
7 years 
(Completed study,1977-92) 
As mentioned in previous (1986-87; 90 & 91) annual reports, the Centre undertook 
a controlled clinical trial of a rifampicin and a non-rifampicin regimen in the treatment 
of leprosy at the Government Royapettah Hospital, Madras. The findings up to five 
years have already been published (International Journal of Leprosy, 1990; 58, 273). 
The patients are being followed up for a further period of 10 years. Interim findings 
up to ten years are presented here. 
Patients who have completed 60 months of treatment were stratified according to 
the average Bacterial Index(BI) value at 57,58,59 and 60 months as 0.5 or more and 
less than 0.5, and were randomly allocated to one of two regimens, namely, clofazimine 
50mg with dapsone(DDS) 100mg daily (CD group) or dapsone 100mg daily (D group) 
for a further period of 2 years. At the end of 84 months, the patients were randomly 
allocated to either dapsone or placebo if their BI value at 84 months was 1.0 or less; 
if the 31 value was more than 1.0; they continued to get the earlier treatment (CD or 
D). 
In all 210 patients (104 rif., 106 non-rif) were admitted to the trial, of whom 159 
had completed 7 years of treatment and were allocated to dapsone (81) or to Placebo 
(78). The remaining 51 patients were not allocated at 84 months (8 had died, 13 had 
migrated and 29 had failed to attend for long periods and 1 patient developed toxicity 
to dapsone). Of the 159 patients, 10 patients (8 DDS, 2 placebo) have been excluded 
(1 died, 2 developed) tuberculosis and were prescribed anti-tuberculosis chemotherapy, 
and 7 failed to attend for more than 6 months). The findings of the remaining 149 
patients (73 DDS, 76 placebo) are presented here. 
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Clinical progress: Clinical progress was assessed by an independent assessor who 
was unaware of the regimen or bacteriological results of the patients, using  scores based 
on semi-quantitative assessments (as described in the previous annual reports). The 
independent assessor's classification of clinical progress is presented m Table 1. Over 
0-84 months, moderate or marked improvement was reported in 66 (97%) in the DDS 
group and 74 (97%) in the placebo group. The corresponding figures were 67 (100%) 
and 62 (98%) over 0.96 months, 60 (100%) and 65 (98%) over 0-108 months, and 62 
(100%) and 63 (100%) over 0-120 months, respectively. Thus, there was excellent clin- 
ical improvement in both series. 
Table 1 
Clinical progress as assessed by the independent assessor 
1. Excluding one patient in the placebo group who was assessed 
2. Excluded for percentage calculation. 
as deteriorated at 107 months and retreated. 
Bacterial Indices: The mean bacterial indices (BI) for the 2 groups at 84, 96, 
108 and 120 months are shown in Table 2. The mean BI was 0.53 for the DDS group 
and 0.49 for the placebo group at 84 months, 0.29 and 0.27 at 96 months, 0.18 and 
0.19 at 108 months and 0.13 and 0.06 at 120 months respectively. 
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Table 2 
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In summary, the interim findings show that patients in the two regimens have 
shown similar improvement clinically and bacteriologically. No additional benefit was 
observed in the group treated with dapsone for 3 years after 84 months. 
CLINICAL STUDIES - IN PROGRESS 
Six month regimen for pulmonary tuberculosis with 2 double- drug combi- 
nations on alternate days for the first two or three months 
(Ongoing study, 1990-94) 
Several highly effective rifampicin-containing short course chemotherapy regimens 
of 6/8 months’ duration have been evolved for the treatment of pulmonary tuberculosis. 
In almost all these regimens, four drugs, namely, rifampicin, isoniazid, pyrazinamide 
and streptomycin or ethambutol are given together in a single dose, either daily or 
intermittently. The number of tablets/capsules to be consumed in a single dose is 
therefore large and the incidence of adverse reactions such as arthralgia and jaundice 
is high with daily regimens. One of the methods that might help to overcome these 
difficulties is to split the four oral drugs into two 2-drug combinations, giving each 
combination on alternate days, thus making each two-drug combination intermittent. 
The Centre is investigating, both at Madras and its unit at Madurai, a regimen 
of rifampicin and ethambutol on one day and isoniazid and pyrazinamide on the next 
day, each combination given thrice a week for the first 2 or 3 months, followed by 
rifampicin and isoniazid twice a week for the next 4 and 3 months, respectively. Since 
both the drug combinations will be given intermittently, the toxicity is expected to 
be low while the efficacy is unlikely to be affected. If the findings are promising, 
this will be a major step towards the possible use of blister packs for drug delivery 
in tuberculosis programmes. These two regimens are to be compared with a control 
regimen of rifampicin, isoniazid, pyrazinamide and ethambutol given together in a 
single dose thrice a week for the first 2 months, followed by rifampicin and isoniazid 
twice a week for the next 4 months. This will provide information as to whether the 
regimen will be equally effective when all 4 drugs are given together or when they are 
given as two 2- drug combinations on alternate days. 
Patients are randomly allocated, irrespective of previous chemotherapy, to one of 
the following regimens: 
1. 2RE3HZ3(alt.)/4RH2(2 alt .): Fully supervised regimen of 6 months’ duration 
consisting of rifampicin and ethambutol on one day and isoniazid and pyrazi- 
namide on the next day., thrice a week for 2 months, followed by rifampicin and 
isoniazid twice a week for the next 4 months. 
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Centre 2 alt. 3 alt. Thrice 
Madras 104 104 106 
Madurai 95 95 94 
Both 199 199 200 
2. 3RE3HZ3(alt.)/3RH2(3 alt.): This is similar to regimen 1, but the initial 
phase is for 3 months, followed by 3 months in the second phase. (For regimens 
1 and 2, Sunday is a drug-free day.) 
Total 
314 
284 
598 
A total of 598 patients (314 at Madras and 284 at Madurai) have been admitted 
up to December 1992 (Table 1). 
So far, 458 patients have completed chemotherapy (246 at Madras and 212 at 
Madurai). Sixteen patients were excluded from analysis, early death (3), pre-treatment 
culture negativity (6), infection with non-tuberculous mycobacteria on admission (2), 
non-tuberculous death (2), chemotherapy modified for adverse reaction (1) and West- 
ern Blot positive (2). Of the remaining 442 patients, 329 (74%) patients received 90% 
or more of chemotherapy during phase I, i.e., 115 (77%) patients in ‘2 alt’, 103 (70%) 
patients in ‘3 alt’ and 111 (77%) in ‘thrice’ regimen (Table 2). 
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3. 2REHZ3(alt.)/4RH2(Thrice): All the 4 drugs are given under supervision in one 
dose thrice a week for 2 months, followed by rifampicin and isoniazid twice a 
week for the next 4 months. 
The dosages are same for all the 3 regimens in both phases, namely, rifampicin 
450 mg, ethambutol 1000 mg and pyrazinamide 1.5 g for patients weighing 40.0 kg 
or less, and 600 mg, 1200 mg and 2.0 g, respectively, for patients weighing 40.1 kg or 
more. The dosages are increased for gain in weight, but not reduced for loss of weight. 
The dosage of isoniaazid is 600 mg, irrespective of body weight. 
Table 1 
Number of patients allocated 
to different regimens 
Regarding chemotherapy during phases I and II, out of the 442 patients, 304 (69%) 
patients received 90% or more of chemotherapy, i.e. 101 (68%) patients in ‘2 alt’, 
99(67%) patients in ‘3 alt’ and 104(72%) patients in ‘thrice’ regimen (Table 3). 
Culture results during treatment: The percentages of culture negativity, based 
on 3 specimens per month, during 1 - 6 months for patients with initially drug sensitive 
organisms are given in Table 4. 
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The proportion with all cultures negative was 26-29% in 1st month, 80-84% in 2nd 
month, 94-99% in the 3rd and subsequent months. The sputum conversion was very 
rapid, the range being 80-84% by 2 months. 
Similarly the proportion of patients who became culture negative month by month 
in resistant patients is given in Table 5. 
The proportion with all cultures negative was 14-17% in 1st month, 48-60% in 2nd 
month, 52-79% in the 3rd month and 48-76% thereafter. 
The study is in progress. 
***** 
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Controlled clinical trial of fully oral short course regimens in Madras and 
Madurai : follow-up phase 
(Ongoing study, 1986-95) 
As explained in previous annual reports (1988, 1989, 1990 and 1991), a controlled 
clinical trial is in progress to investigate three fully oral regimens of 6 or 8 months’ 
duration, with varying frequencies of attendance, different rhythms and full, partial or 
no supervision of drug intake. Patients are randomly allocated, irrespective of previous 
chemotherapy, to one of the following regimens. 
1, 2EHRZ7 (ow)/6EH7 (tm) : This is a fully self- administered daily regimen 
of 8 months’ duration. Ethambutol 600 mg, isoniazid 300 mg, rifampicin 450 mg and 
pyrazinamide 1.5 g daily are prescribed for the first 2 months, followed by ethambutol 
600 mg and isoniazid 300 mg daily for the next 6 months. The patients are required 
to attend the clinic once a week during the first 2 months and twice a month during 
the next 6 months for drug collection. 
2. 2EHRZ2/4EHR2 (tw) or 2EHRZ2 /4EHR2 (ow) : This is a twice- weekly 
regimen of 6 months’ duration. The patients receive ethambutol 1200 mg, isoniazid 
600 mg, rifampicin 450 mg and pyrazinamide 2.0 g during the first two months and 
ethambutol, isoniazid and rifampicin in the same dosages during the next 4 months. 
Half the patients, by random allocation, receive fully supervised chemotherapy at the 
clinic, necessitating twice weekly attendance throughout. The other half attend only 
once a week, when one dose is given under supervision and the other dose is supplied 
for self- administration (3 or 4 days later). 
3. 2HRZ2/4HR2 (tw) or 2HRZ2/4HR2 (ow) : This is similar to regimen 2, 
but without ethambutol. 
The study was undertaken at the Centre and its unit at the Government Rajaji 
Hospital, Madurai (Dean : Dr.Veerababu). Patients at Madurai were admitted on the 
basis of smear examination done at Madurai Unit. For patients admitted to the study, 
multiple sputum specimens are transported to the Centre at Madras, for culture and 
sensitivity tests. Close liason is maintained by the Centre with the Madurai Unit by 
periodic visits by the Centre’s staff. 
The intake to the study was completed in October, 1990. A total of 1204 patients 
(601 in Madras and 603 in Madurai) have been admitted to the study. Of these, 113 
patients (62 at Madras and 51 at Madurai) have been excluded for various reasons: 21 
were not eligible for admission, 2 developed pneumo-thorax in the first week, 6 died 
of non-tuberculous causes, 1 had a change of treatment for toxicity and 83 patients 
missed 25% or more of their chemotherapy. Of the remaining 1091 patients, 825 had 
organisms sensitive to rifampicin and isoniazid, 227 had organisms resistant to isoniazid 
alone, 38 had organisms resistant to rifampicin and isoniazid and one had resistance 
to rifampicin alone. 
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The mean age of the patients on admission was 30 years, the mean weight was 
39.9 kg and 67% of the patients were males. The response to chemotherapy of these 
patients has already been presented in 1991 annual report. 
Relapse requiring treatment : Bacteriological relapse requiring treatment is 
defined as 2 or more positive cultures in a 2-month period, at least one of which has a 
growth of 20 colonies or more, associated with a positive smear. A total of 777 patients 
with initially drug-sensitive organisms have completed 16/18 months of follow-up after 
stopping treatment. Relapse requiring treatment (Table 1) occurred in 13 (4.5%) of 
290 patients in regimen 1, 26 (10.1%) of 258 patients in regimen 2, and 20 (8.7%) of 
229 patients in regimen 3. 
Total Relapse Month of relapse 
Regimen assessed requiring Rx. after stopping Rx. 
No. % 1-3 4-6 7-12 13-16/18 
2EHRZ7/6EH7 290 13 4.5 10 2 0 1 
(2.1- 6.9 ) 
2EHRZ2/4EHR2 258 26 10.1 14 7 3 2 
2HRZ2/4HR2 229 20 8.7 13 3 3 1 
(6.4-13.8) 
(5.1-12.3) 
Regimens 
2 EHRZ2/4EHR2 & 
2 HRZ2/4HR2 & 
2EHRZ7/6EH7 
2EHRZ7/6EH7 
The 95% confidence limits for the regimen-wise relapse rates are shown in paren- 
theses in Table 1. Confidence limits for the differences between the relapse rates of 
any two regimens are given in Table 2. 
95% confidence limits for the 
difference between relapse rates(%) 
Lower limit Upper limit 
+ 1.2 + 10.0 
- 0.2 + 8.6 
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Table 1 
Bacteriological relapse rates during 16/18 months follow-up 
in patients with initially isoniazid sensitive organisms 
1. Figures in parentheses are 95% confidence limits of relapse rates 
Table 2 
Confidence limits for the difference between relapse rates 
2 EHRZ2/4EHR2 & 
2EHRZ2/6EH2 - 3.8 + 6.6 
The difference in the relapse rates between the four-drug intermittent regimen and 
the daily regimen is statistically Significant (P<0.05) as the lower limit of the confidence 
interval is positive with a value of 1.2. The other two differences in the relapae rates 
are not statistically significant, as zero is contained in both the confidence intervals 
(indicated by the negative lower limit). The upper limits of confidence intervals indicate 
as to how large the difference could be between the corresponding relapse rates. 
The relapse requiring treatment during 16/18 months follow-up of 149 patients with 
initially isoniazid-resistant organisms is given in Table 3. Six (8%) of 75 patients in 
regimen 1, 11(23%) of 47 patients in regimen 2 and 4(15%) of 27 patients in regimen3 
have relapsed, the majority occurring within 3 months after stopping treatment. The 
95% confidence limits for the relapse rates are shown in Darenthesee in Table 3. 
1. Figures in parenthesea are 95% confidence limits of relapse rates. 
Follow-up of the patients is continuing, . 
***** 
Treatment regimens for patients who fail or relapse on short course 
chemotherapy 
(Ongoing study,1987) 
Pulmonary tuberculosis patients who have been treated with short course regimens 
and who 
(i) show a serious clinical deterioration, 
(ii) have a persistent radiographic deterioration, 
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(iii) 
(iv) 
have an unfavourable bacteriological response, or 
have a bacteriological relapse requiring retreatment, 
are prescribed an appropriate regimen depending on the last available drug sensitivity 
test results. 
The chemotherapeutic regimens are as follows: 
Patients with bacilli sensitive to isoniazid and rifampicin: Such patients are 
admitted by random allocation to either 3EHRZ2/6HR2, or 3EHRZ2/9HR2, namely 
ethambutol 1200 mg plus igoniazid 600 mg plus rifampicin 450 mg plus pyrazinamide 
2.0 g twice a week for the first 3 months, followed by isoniazid plus rifampicin in the 
same dosages twice a week for either the next 6 months (9m regimen), or the next 9 
months (12m regimen). Every dose is administered under supervision. 
Status 
No. with information up to 1 year 
No. of Patients 
9m regimen 12m regimen 
40 40 
2 
0 
0 
Change of Rx due to adverse drug reactions 
Early death 
Non-TB death 
0 
1 
1 
< 75% of chemotherapy 
No. in analysis 
Favourable response 
Unfavourable response 
10 8 
28 30 
27 27 
1 3 
Treatment was intensified to daily drug therapy in 2 patients in the 7th and 12th 
months, respectively; the former had produced negative cultures at the 1st month and 
the latter, from the 2nd month to the 8th month, for the third patient, the regimen was 
developed isoniazid resistance from the 2nd month. The fourth patient (9m regimen) 
had been persistently culture positive and had developed resistance to isoniazid at the 
changed in the 6th month as the patient had been persistently culture positive and had 
3rd month. 
Patients with bacilli resistant to isoniazid: Such patients are admitted to 
6SERZ2/6ERZ2, or 6KERZ2/6ERZ2 and prescribed streptomycin 0.75 g or if the bacilli 
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So far, 107 patients have admitted to these regimens. Of 80 eligible cases 
for whom information up to one year is available, 22 are excluded (Table 1). Of the 
remaining 58 (28 in 9m regimen and 30 in 12m regimen), 54 (27 in 9m regimen and 27 
in 12m regimen) had a favourable bacteriological response. Four patients showed an 
unfavourable bacteriological response, without any associated clinical or radiographic 
changes. Of the 4, three patients (all 12m regimen) had a change of chemotherapy. 
Table 1 
Distribution of patients with sensitive 
bacilli to H and R according to their 
status during and at the end of treatment 
are resistant to streptomycin, kanamycin 1.0 g plus ethambutol 1200 mg plus rifampicin 
450 mg plus pyrazinamide 2.0 g twice a week for the first 6 months, followed by 
ethambutol plus rifampicin plus pyrazinamide in the same dosages twice a week for 
the next 6 months (total 12 months). Every dose is administered under supervision. 
6SERZ2/6ERZ2: So far, 55 patients have been admitted to this regimen. Of 39 
eligible cases for whom information up to 1 year is available, 14 are excluded (Table 2). 
Of the 25 in analysis, 20 had a favourable bacteriological response. The remaining 5. 
have shown an unfavourable bacteriological response. Three patients required change 
of chemotherapy. Of these, 1 had positive culture persistently; his treatment was 
changed at the 6th month from intermittent to daily chemotherapy. One patient had 
produced negative cultures at the 2nd and 3rd months, positive cultures from the 4th 
month onwards and developed streptomycin resistance at the 5th month, the treatment 
was changed at the 11th month. One other patient had positive cultures persistently 
and his treatment was changed at the end of the specified chemotherapy. The other 
2 patients had produced negative cultures from the 1st and 2nd months and positive 
cultures from the 5th and 10th month onwards, respectively. None of these 5 patients 
had associated clinical or radiographic deterioration. 
6KERZ2/6ERZ2: So far, 54 patients have been admitted to this regimen. Of the 
39 eligible cases, 6 are excluded(Tab1e 2). Of the 33 in analysis, 25 had a favourable 
bacteriological response. Of the remaining 8 patients, 6 had a change of treatment be 
tween 5 and 10 months for persistent culture positivity; and 5 had developed rifampicin 
resistance. One other patient had his treatment changed to daily chemotherapy at the 
6th month as he got himself admitted in a hospital; he also had persistent culture 
positivity. The other patient completed treatment, having been culture negative from 
the 2nd to the 10th month, but produced two positive cultures in the last 3 months of 
treatment. 
Patients with bacilli resistant to isoniazid and rifampicin: Such patients 
are admitted to 3S3EmbEthZ7/9EmbEthZ7 or 3K3EmbEthZ7/9EmbEthZ7, and pre- 
scribed streptomycin 0.75 g thrice a week or, if the bacilli are resistant to streptomycin, 
kanamycin 1.0 g thrice a week, plus daily ethmbutol 600 mg plus ethionamide 500 
mg plus pyrazinamide 1.5 g for the first 3 months, followed by daily ethambutol plus 
ethionamide plus pyrazinamide in the same dosages for the next 9 months (total 12 
months). Throughout the 12 months, the patients attend thrice a week, when they 
receive that day's dose under supervision and are supplied with drugs for the following 
day(s) for self- adminisration. 
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Table 2 
Number of patients according to regimen and 
their response to treatment 
3S3EmbEthZ7/9EmbEthZ7: So far, 24 patients have been admitted to this 
regimen. Of the 17 eligible cases, 9 are excluded (Table 2). Of the remaining 8 patients, 
4 had a favourable response. Of the 4 with unfavourable response, 2 persistently 
had positive cultures and had a change of treatment at the 7th and 10th months, 
respectively. Two patients had negative cultures from the 1st month, but produced 
positive cultures from the 5th month onwards; one of these had a change of treatment 
at the 8th month. 
3K3EmbEthZ7/9EmbEthZ7: So far, 34 patients have been admitted to the 
regimen. Of the 30 eligible cases, 11 are excluded (Table 2). Of the 19 in analysis, 
7 had a favourable bacteriological response. Of the remaining 12, 10 had persistent 
positive cultures and had a change of treatment between 4 and 12 months. One patient 
had negative cultures from the 1st to the 3rd month, produced positive cultures from 
the 4th month., and had a change of treatment at the 6th month. One patient died of 
active pulmonary tuberculosis. 
The intake to all the regimens is continuing. 
***** 
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Short course chemotherapy in pulmonary tuberculosis in children 
(Ongoing study, 1992-96) 
Evaluation of various therapeutic regimens for the treatment of pulmonary tuber- 
culosis has been the major point of focus for more than 3 decades. The accent has 
been on short course chemotherapy (SCC). Though there are many reports available on 
SCC in adults, information regarding the same for tuberculosis in children is limited. 
Hence this Centre has started an SCC study in pulmonary tuberculosis in children, 
in collaboration with the Institute of Child Health (ICH), Egmore, Madras. Patients 
are selected from children referred from Tuberculosis Research Centre and ICH. To be 
eligible for admission, children should be aged between 1 and 12 years and should not 
have had more than 2 weeks of previous anti-tuberculous chemotherapy. The eligible 
children are classified into two categories of cases, definite cases (Category A) and 
probable cases (Category B). The definite cases must have any one of the following 
abnormalities seen on x-ray before admission : 
(a) primary focus plus hilar adenitis, 
(b) mediastinal glandular enlargement, or 
(c) parenchymal lesion suggestive of miliary tuberculosis or progressive primary tu- 
berculosis. 
A history of contact with a known bacillary case of pulmonary tuberculosis or a 
positive tuberculin test with induration (1 TU) of 10 mm or more will be confirmatory. 
While definite cases of pulmonary tuberculosis (Category A) are directly started on 
anti-tuberculosis treatment, those with radiographic abnormality, not conclusive of 
pulmonary tuberculosis, (Category B), are administered antibiotics for a period of 10- 
14 days and the chest X-ray is repeated. If the abnormality persists they are admitted 
to the study. 
Patients in each category are randomly allocated to one of the following two regi- 
mens: 
Regimen I : 9HR : Rifampicin and isoniazid daily for 9 months. Patients will 
attend the clinic once a week, the drugs are administered together under supervision 
on the day of attendance and supplied for the rest of the days. 
Regimen II : 2H3R3Z3/4H2R2 : Rifampicin, isoniazid and pyrazinamide thrice 
a week for the first 2 months followed by isoniazid and rifampicin twice a week for the 
next 4 months. All the drugs are administered together under supervision. 
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The dosages are as follows: 
Isoniazid: 6 mg/kg for daily and 15 mg/kg for the thrice-twice weekly 
phase. 
Rifampicin: 12 mg/kg. 
Pyrazinamide: 45 mg/kg. 
Examinations/investigations on admission : (a) general clinical examination, 
(b) Mantoux test, (c) A full plate radiograph of the chest, (d) liver function tests, (e) 
gastric lavage and sputum (wherever possible) cultures for AFB (f) urine tests and (g) 
haematological investigations. In patients with lymphgland enlargement, lymphnode 
biopsy will be done for histopathological and bacteriological examination. Chest ra- 
diographs will be taken at 2 weeks, 2nd, 6th and 9th month of treatment for both the 
categories of patients. 
It is proposed to admit 200 patients(100 to each regimen). So far, 32 patients have 
been admitted (15 to Regimen I and 17 to Regimen II). 
***** 
Collaborative controlled clinical trial of tuberculous lymphadenitis 
(Ongoing study, 1988-93) 
Our Madurai Unit is conducting a controlled clinical trial in tuberculous lym- 
phadenitis in collaboration with the Paediatric (Dr.A.J.Thiruthuvathas) and Adult 
Surgery (Dr.D.Anantharaj) Departments of the Govt.Rajaji Hospital, Madurai. Pa- 
tients residing in or around Madurai with biopsy proved tuberculous lymphadenitis are 
admitted to the study. Previous anti-TB therapy is not a contra-indicating factor for 
admission. The hietopathology slides of the lymph node biopsy are read by the Profes- 
sor of Pathalogy (Dr.V.Ananthalakshmi), Madurai Medical College and bacteriological 
investigations are done in Madras at our Centre. 
Patients admitted to the study are randomly allocated to either a 6-month daily 
regimen of rifampicin and isoniazid (6RH7) supplied twice a month for self administra- 
tion, or a 6-month fully supervised twice weekly regimen of rifampicin and isoniazid 
with pyrazinamide for the first two months (2RHZ2/4RH2). The drugs are prescribed 
in uniform dosage for adults, while a weight-adjusted dosage schedule is used for chil- 
dren. Patients are treated on an out-patient basis. Surprise home visits are done for 
pill counts for patients allocated to the self-administered regimen (6RH7). 
Patients are assessed clinically every month upto 12 months, every 3 months upto 
24 months and every 6 months thereafter. At the end of chemotherapy, the clinical 
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response is assessed by an independent assessor. The response is defined as follows: 
Children 
Adults 
Total 
(a) favourable, if the nodes have regressed in size to 10 mm or less and if any sinus 
(b) doubtful, if significant residual nodes (>10 mm diameter) are palpable and 
(c) unfavourable, if treatment needs to be extended or changed. 
present on admission has healed, 
Age Male Female Total 
(Yrs) 
<6 17 8 25 
7-12 31 18 49 
13-30 17 101 118 
31-40 5 19 24 
> 40 1 4 5 
71 150 221 
Repeat lymph node biopsy is done for patients with significant residual lymphadenopa- 
thy. Patients will be followed up for 5 years from the start of treatment. 
Children 
Adults 
Results : A total of 244 patients have been admitted to the study (upto Dec.31, 
1992) and 232 have completed treatment. After excluding 11 patients, 221 are available 
for interim analysis. Of these 221, 147(67%) were adults; 150(68%) were females 
(Table 1) 
Culture NTM Total1 
Positive Negative 
54 (76%) 15 2 71 
99 (69%) 38 7 144 
Table 1 
Distribution of patients by sex and age 
The results of the bacteriological examination of lympnode biopsy specimen for 
M.tuberculosis are shown in Table 2. It is observed that 76% of children and 69% of 
adults had positive cultures for M.tuberculosis prior to start of chemotherapy. 
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Table 2 
Results of bacteriological examination of 
lymphnode biopsy specimens of M.TB. 
1.Cultures were not available for 3 children and 3 adults. 
Response to treatment : The response was favourable in 32 (89%) out of 36 
children in 6 RH7 and in all 38 (100%) in 2RHZ2/4RH2. In adults, 70 (92%) out of 
76 in 6 RH7 and 69 (97%) out of 71 in 2RHZ2/4RH2 had a favourable response(Table 
3). Three adult patients in 6 RH7 had an unfavourable response, requiring a change 
or extension of treatment. The response for 9 patients (4 children and 5 adults) was 
classified as doubtful at the end of treatment. Repeat lymph node biopsy was done 
in 7 of these 9 patients (3 children and 4 adults). In 6, the lymph node culture was 
negative though the histopathology was suggestive of tuberculosis and, for the other 
patient, both histopathology and culture were negative. 
Total Favourable Doubtful 
pts. No. % No. % 
Table 3 
Unfavourable 
No. % 
36 
38 
76 
71 
Children 
6 RH7 32 89 4 11 0 0 
38 100 0 0 0 0 
70 92 3 4 3 4 
69 97 2 3 0 0 
2RHZ2/4RH2 
6 RH7 
Adults 
The study is in progress. 
***** 
Collaborative study of abdominal tuberculosis : follow-up phase 
(Ongoing study, 1983 - 2001) 
As mentioned in previous annual reports (from 1986 to 1991), the Centre ham carried 
out a collaborative study on abdominal tuberculosis. The objectives of this study were: 
a) to identify the clinical and laboratory profiles of peritoneal, intestinal 
and mesenteric tuberculosis in South Indian patients, and 
b) to compare the efficacy of short-course regimen with that of a standard 
regimen in the treatment of abdominal tuberculosis. 
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Response to treatment 
2RHZ2/4RH2 
A secondary objective was to develop, from the findings of this study, satisfactory 
criteria for diagnosis, assessment of response and identification of relapse in abdom- 
inal tuberculosis. The study was conducted in collaboration with the Departments 
of Medicine and Medical and Surgical Gastro- enterology of the Government General 
Hospital, Madras, and the Govt. Peripheral Hospital, Anna Nagar, Madras. 
A plain radiograph of. the abdomen, barium meal and barium enema series and a 
chest radiograph were taken. Two sputum specimens were examined by smear and 
culture in patients suspected to have pulmonary tuberculosis. 
Patients with bacteriological, histopathological or radiological confirmation, as well 
as those with a clinical condition highly suggestive of abdominal tuberculosis, were 
admitted to the study. Patients were randomly allocated to either of the following 
regimens. 
Regimen 1 (2RHZ/4RH - rifampicin series): Rifampicin 10 mg/kg plus iso- 
niazid 300 mg plus pyrazinamide 30 mg/kg daily for 2 months, followed by rifampicin 
10 mg/kg plus isoniazid 300 mg daily for the next 4 months. 
Regimen 2 (SEH/EH- non-rifampicin series): Streptomycin 0.75 g plus 
ethambutol 25 mg/kg plus isoniazid 300 mg daily for 2 weeks, followed by etham- 
butol 15 mg/kg plus isoniazid 300 mg daily for the next 50 weeks. 
Results up to 84 months: Of the 155 patients, who were either symptom free 
or clinically improved at the end of treatment, 70 patients (40 rifampicin, 30 non- 
rifampicin) completed 84 months of follow-up. Three patients ( 1 rifampicin series and 
2 non-rifampicin series) among them required retreatment, one following surgery for 
intestinal obstruction as advised by the surgeon even though there was no histopath- 
logical or bacteriological evidence of relapse, one for renal tuberculosis and the remain- 
ing one for suspected tuberculous lymphadenitis which was found to be malignancy 
later. One patient (rifampicin series) died due to tuberculosis and five patients (3 
rifampicin, 2 non-rifampicin series) died due to non-tuberculous causes. One patient 
(non-rifampicin series) who was lost for follow-up in the 16th month was asymptomatic 
at that time. All the remaining 60 patients are doing well at 84th month and it ie grat- 
ifying to note that none of these 70 patients had relapse with abdominal tuberculosis. 
Adult patients with clinical evidence of tuberculosis of the abdomen were subjected 
to appropriate diagnostic procedures such as laparoscopy, laparotomy, colonoscopy or 
liver biopsy and in cases with ascites, percutaneous peritoneal biopsy, for obtaining 
material for histopathological and bacteriological examinations. Ascitic fluid, when 
available, was subjected to cytological examination, biochemical investigations and 
bacteriological examinations. A complete hemogram was done and 3 early morning 
urine specimens examined by culture for M.tuberculosis 
These patients will be followed-up up to 120 months from start of treatment. 
***** 
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Collaborative study of brain tuberculoma : follow up phase 
(Ongoing study, 1992-96) 
This study was undertaken in collaboration with the Institute of Neurology, Govt.General 
Hospital (Prof.S.Kalyanaraman), Madras and Railway Hospital (Prof.Zaheer Ahamed 
Sayeed), Perambur. 
The objectives of the study were : 
1. to evaluate the efficacy of short course regimens for treating tuberculoma of the 
brain and 
2. to study the CT scan appearance, before, during and at the end of chemotherapy 
and upto 60 months after start of treatment. 
A secondary objective was to study the role of surgery in the treatment of brain 
tuberculoma. 
All cases admitted to the study were randomly allocated to one of the following 
9-month regimens: 
Regimen I : 3RHZ7/6RH2 (daily) 
Regimen II : 3RHZ3/6RH2 (intermittent) 
The detailed findings on the response to the Short Course Chemotherapy of brain 
tuberculoma patients have been presented in 1991 annual report. This report mainly 
deals with comparison of the status of the patients at 9th month and 24th month after 
start of treatment. A total of 144 patients were admitted to the study and 36 patients 
were excluded for various reasons. Of the remaining 108 patients, 54 patients had no 
clinical deficit at the start of treatment; at the end of 9 months of chemotherapy, 97 
(90%) patients were normal clinically, compared to 94 (87%) at 24 months. 
At 9 months, 8 (7%) of 108 patients had residual neurological deficit, 3 with post- 
papilloedemic optic atrophy alone, 2 with residual hand grip weakness and the other 
3 with optic atrophy with hemiparesis. At 24 months, 11 (10%) patients had residual 
neurological deficit as 3 new patients developed fresh deficit due to convulsions after 
9 months. 
CT scan progress till the end of Chemotherapy was available in 91 patients as scan 
could not be taken for 17 patients due to various reasons (total surgical removal (3), 
death (2), change of treatment (1), scan not available (11)). 
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Changes as assessed by CT scan at 9 and 24 months are shown in Table 1. At 
9 months, CT scan lesions were resolved completely in 78%, decreased in 18%, static 
in 2%, increased in size in 1% and fresh lesion appeared in 1% (new lesion appeared 
before 9 months in a female patient who had histopathologically confirmed tuberculoma 
following craniotomy biopsy. As she was clinically doing well at 9 months, additional 
chemotherapy was not given and was kept under observation). At 21 months, CT scan 
was read in 89 patients of whom 78 (88%) had a total resolution of the lesions and 11 
(12%) had partial resolution. 
Table 1 
Changes as assessed by- CT scan 
In 24 months period, none had a relapse requiring treatment. The 5 year follow-up 
is continuing. 
***** 
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Collaborative clinical study of cutaneous tuberculosis 
(Ongoing study, 1992-95) 
There have been only two studies on cutaneous tuberculosis where drug trials 
were conducted using multiple drug regimens elsewhere. In view of the paucity of 
information on these trials, a pilot study on cutaneous tuberculosis was started in 
P. Yesudian) and Department of Dermatology, Govt.Stanley Hospital, Madras (Prof. 
S.Premalatha) with the, following objectives: 
collaboration with Department of Dermatology, Govt. General Hospital, Madras (Prof. 
1. to evolve and establish suitable criteria for diagnosis of cutaneous tu- 
berculosis and 2. to study the feasibility of conducting controlled clinical 
studies in cutaneous tuberculosis to evolve efficacious regimens of treat- 
ment. 
The patients diagnosed clinically as having cutaneous tuberculosis by the derma- 
tologist are admitted to the pilot study. The following. investigations are carried out 
prior to admission: 
3 Complete hemogram, 2) Biochemical investigations, 3) Dermatological as- 
5) Biopsy of the lesion for histopathology and 
6) Mantoux test with 1 TU of PPD (RT 23 with 
sessment, 
bacteriological examinations and 
Tween 80) read at the end of 1,2,3,4,7, 14 and 21 days. 
Adult patients (aged 12 years or more) admitted to the study are treated with 
rifampicin (450 mg) and isoniazid (300 mg) daily for 9 months, while children (below 
12 years of age) are treated with a weight adjusted dosage of rifampicin( 10 - 12 mg/kg) 
and isoniazid(5 mg/kg). The drugs are supplied once a week for self administration at 
home. The patients are assessed at TRC and also at either collaborating hospital at 
monthly intervals during treatment phase and at 3 monthly intervals upto 24 months. 
4) Clinical photography, 
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Table 1 
Pre-treatment characteristics 
1. 10 patients had disease at multiple sites. 
So far, a total of 59 patients have been admitted to the study. The distributions 
of the pre-treatment characteristics of the patients are shown in Table 1. Thirty-five 
(59 %) of 59 patients are less than 25 years on admission and only 10(17 %) are aged 
more than 45 years. Foot is most frequently affected part of the body amounting to 
42 %. Forty-nine (83 %) patients have the disease lupus vulgaris or verrucose cutis 
type. 
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Of the 43 patients for whom the results of histopathology examination and bacteri- 
ology are available, the diagnosis is confirmed by histopathology only in 37 (86%) 
whereas bacteriological confirmation of the disease was possible only in 22 (51%) 
patients (Table 2). 
The intake is continuing and the study is in progress. 
***** 
Role of bronchoalveolar lavage in the diagnosis of sputum smear negative 
but x-ray positive pulmonary tuberculosis in adults 
(Ongoing study, 1988-93) 
Bronchoalveolar lavage studies (BAL) using flexible fiberoptic bronchoscope were 
carried out in sputum smear negative, but X-ray positive pulmonary tuberculosis pa- 
tients to assess the role of BAL in the diagnosis of tuberculosis in comparison with 
sputum culture examination. Patients with respiratory symptoms of less than 6 months 
duration with radiographic abnormalities suggestive of tuberculosis and without previ- 
ous anti-tuberculosis treatment were eligible for the study. All patients had 6 sputum 
smears negative for acid fast bacilli (AFB). Sputa are then processed for culture ex- 
amination. Informed consent was obtained from each subject and then BAL were done 
with instilling 100 ml saline in five 20 ml aliquots at each segment and the fluids were 
aspirated using a clinical suction apparatus. The study was done in two phases. 
Phase I: The BAL were done from radiologically abnormal lobe and contralateral 
middle lobe or lingula. The fluids recovered from both sites were pooled and an 
aliquot from the pooled specimen was used for bacteriological examination by smear 
and culture. 
Of 49 suspected patients investigated (Table 1), 17 patients had pulmonary tu- 
berculosis as revealed by isolation of M.tuberculosis in sputum cultures; 9 had both 
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sputum and lavage cultures positive for M.tuberculosis , whereas 8 were diagnosed 
by sputum culture alone. Thus BAL specimens, when pooled, provided diagnosis only 
in 53% of the patients proved to be tuberculosis by sputum culture. BAL smear was 
positive only in one patient and none had BAL culture positivity without positive 
sputum culture. 
Table 1 
Phase II: Because of poor yield of M.tuberculosis from pooled specimens, lavages 
were done first from radiologically normal lobe and then from contralateral radiolog- 
ically abnormal lobe during Phase II. An aliquot of BAL fluid from each lobe was 
separately subjected to bacteriological examination. 
Out of 71 suspected patients during phase II (Table 2), 33 patients had pulmonary 
tuberculosis as revealed by positive culture of M.tuberculosis in sputum. Of these 
33, 24 (73%) had both sputum and BAL specimens were positive for M.tuberculosis 
whereas 9 were proved to be tuberculosis by growth of M.tuberculosis in sputum alone. 
Thus, when BAL specimens were cultured separately from radiologically abnormal and 
normal lobes, the yield from BAL was 73% of 33 patients proved to be tuberculous by 
sputum culture examination. Only 3 patients had BAL smears positive for AFB and 
none of the cultures had BAL positivity without sputum culture positivity. 
Table 2 
Culture results of BAL specimens processed 
50 
Culture results of pooled BAL specimens against 
routine sputum specimens-phase I 
separately against routine sputum specimens-phase II 
In this study, the culture positivity rate is found to be more with sputum speci- 
mens. This may be due to the dilution of the epithelial lining fluid by the externally 
instilled saline during BAL procedure. Though the positivity rata in BAL specimens 
had gone up when BAL specimen from radiologically abnormal lobe was analysed sep- 
arately, the positivity rate has not reached the same level as that of sputum culture 
examination. Therefore, BAL, done by instillation of saline is not superior to spu- 
tum culture examination for diagnosis of smear negative but x-ray positive pulmonary 
tuberculosis. 
Further studies utilising centrifuged specimens of BAL, bronchial aspirations with- 
out addition of saline, bronchial brush biopsies and post-bronchoscopy sputum spec- 
imens are required to assess the role of fiberoptic bronchoscopy in the diagnosis of 
sputum smear negative pulmonary tuberculosis. 
***** 
Role of bronchoalveolar and gastric lavages in the diagnosis of pulmonary 
tuberculosis in children 
(Ongoing study 1992-93) 
Bacteriological diagnosis of pulmonary tuberculosis in children is difficult because 
of the paucibacillary nature of the disease and difficulty in obtaining sputum specimens 
from children. Most patients are now treated on the basis of clinical presentation and 
chest roentgenographic appearances. This usually results in overdiagnosis and unnec- 
essary treatment of children with anti-tuberculous drugs. Since a reliable immuno- 
diagnostic test for tuberculosis is not currently available, a study has been planned to 
evaluate the role of bronchoalveolar and gastric lavages for bacteriological diagnosis of 
childhood pulmonary tuberculosis. Although bronchoalveolar lavage is not at present 
a standardised procedure in children, the bronchial and alveolar specimens obtained 
during flexible fibreoptic bronchoscopy are sufficient for bacteriological examination. 
This study is being carried out in collaboration with the Institute of Child Health and 
Hospital for Children, Madras (Professor N. Somu as Principal Investigator). 
Children aged 1-12 years attending the Institute of Child Health and presenting 
with respiratory symptoms and persistent chest radiographic findings suggestive of 
pulmonary tuberculosis are evaluated. Bronchoalveolar and gastric lavages are done 
at the Institute of Child Health, while bacteriological investigations are carried out at 
TRC. So far, 38 patients have been admitted. 
The study is in progress. 
***** 
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Controlled clinical study of multi-drug therapy for multi-bacillary leprosy 
(Ongoing study, 1988-95) 
As mentioned in the previous (1988-1991) annual reports, the Centre has under- 
taken a controlled clinical trial to assess the relative efficacies of pyrazinamide and 
rifampicin in combination with clofazimine and DDS in the treatment of multibacil- 
lary leprosy, at the Govt. Royapettah Hospital, Madras. 
The following four regimens are being investigated: 
I. NLEP: Rifampicin 12 mg/kg body-weight once a month in addition 
to a daily dose of 12 mg/kg body-weight in the first 14 days, clofazimine 
300 mg once a month in addition to a daily dose of 100 mg for the first 
14 days and 50 mg daily thereafter, and dapsone 100 mg daily, for a total 
period of 24 months (regimen in use in the National Leprosy Eradication 
Programme). 
II. NLEP + Addition of PZA: Rifampicin, clofazimine and dapsone as 
in regimen I plus pyrazinamide 35 mg/kg body-weight daily for the fire 3 
months and 50 mg/kg body-weight twice-weekly for the next 9 months. 
III. NLEP + Extension of Rif.: Clofazimine and dapsone as in regimen 
I, plus rifampicin 12 mg/kg body-weight, daily for the first 3 months, twice 
weekly for the next 9 months and once a month for the next 12 months. 
IV. NLEP + Extension of Rif. & Addition of PZA: Clofazimine, 
dapsone and pyrazinamide as in regimen II and rifampicin as in regimen 
III. 
Chemotherapy has been stopped at the end of 24 months irrespective of Bacterial 
Index (BI) value unless the patient had reactions and was getting steroids (chemother- 
apy was extended for one more year and reviewed in such cases). 
It is proposed to admit 25 patients to each regimen; 80 patients have been admitted 
so far to the study. In all, 64 patients (16 NLEP, 17 NLEP + Z, 16 NLEP + Ext. 
of Rif. and 15 NLEP + Ext. of Rif.+ Z) have information upto 24 months. Of 
these, 9 patients were excluded (3 died due to reasons other than leprosy -carcinoma 
of the stomach , suicide, late complication (stricture oesophagus) of attempted suicide 
by swallowing sulphuric acid, treatment was changed in one due to jaundice; 4 due 
to non-cooperation and one patient migrated) and the findings in the remaining 55 
patients (15 reg.I; 13 reg.II; 15 reg.III and 12 reg.IV) are presented here. 
Clinical progress: Clinical progress was assessed by an independent asseasor (us- 
ing scores based on semi-quantitative assessments, as described in the previous annual 
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reports), who was unaware of the regimen or bacteriological status of the patients. 
Combining all the four treatment groups, moderate or marked improvement was ob- 
served in 19 (37%) of 51 patients assessed during 0-3 months, 28 (55%) of 51 during 
0-6 months, 30 (55%) of 55 during 0-12 and 48 (89%) of 54 during 0-24 month. 
Bacterial Indices: The mean bacterial indices were 4.55 lor reg.I, 4.35 for reg.II, 
3.89 for reg.III and 4.24 for reg.IV on admission and 3.08, 3.38, 2.78 and 2.86 at the 
end of treatment period respectively. The mean falls in BI are 1.47, 0.97, 1.11 and 
1.38, in the 4 regimens, respectively. 
Any additional benefit derived from the supplement of rifampicin and pyrazinamide 
may perhaps be seen in the follow-up period. 
***** 
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LABORATORY STUDIES - COMPLETED 
Early bactericidal action of pulsed exposure to REHZ3 and RE3HZ3 (alt.) 
in pulmonary tuberculosis patients 
(Completed study, 1991-92) 
In an earlier study (annual report 1990), using an in vitro system, it was found that 
R, E, H and Z together thrice-weekly and RE on one day and HZ on the next day thrice 
weekly had equally good early bactericidal action (EBA) on M.tuberculosis strains. 
The present study was undertaken in tuberculosis patients admitted to an ongoing 
study of short course chemotherapy (SCC) regimens. The EBA of administering RE on 
one day and HZ on the next day, each combination given thrice weekly (RE3HZ3(alt.)), 
in comparison with REHZ given together thrice weekly (REHZ3) was determined by 
conducting serial sputum viable count examinations in these patients. 
Estimation of viable counts of tubercle bacilli was made from a single overnight 
collection specimen of sputum collected on days 0, 2, 4, 9 and 16 for both regimens, 
Patients with drug-resistant organisms, all patients with negative cultures at the first 
time point, and those who failed to attend or whose culture was contaminated, or 
results were not available for other reasons at any of the time points, were excluded. 
There remained 49 patients in the analyses (21 in REHZ3 and 28 in RE3HZ3(alt.)). 
The mean log colony forming units (cfu) of M.tuberculosis (per ml) in serial sputum 
samples from the two groups of patients before start of treatment (day 0) and on days 
2, 4, 6 and 16 during treatment are presented in Table 1. In both groups of patients, 
there was a significant reduction (p< 0.02) in the cfu of M.tuberculosis (per ml) of 
sputum during the first 2 days of treatment. 
The average fall per day in the number of viable bacilli in the sputum of these 
patients is presented in Table 2. 
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In both groups of patients, the EBA of the REHZ3 and RE3HZ3(alt.) regimens, 
estimated in terms of change in log cfu/ml/day during the first two days of treatment 
was higher (0.71 and 0.46, respectively) compared to the average fall in the subsequent 
days (2 & 16 days) of treatment (0.21 and 0.19, respectively). The differences between 
the two treatment groups in the EBA and the fall in counts during 2 - 16 days were 
not statistically significant (p>0.3). Analysis of covariance also showed no relationship 
between initial counts and the rate of fall in counts (p>0.3). 
The results of this study-in tuberculosis patients is in conformity with the results 
obtained from an independent in vitro study. Both regimens had similar early bacte- 
ricidal action. The results suggest that splitting up REHZ into RE on one day and 
HZ on the next day in SCC regimens may not affect the bactericidal action of the 
regimens. 
***** 
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Methodology for evaluation of early bactericidal effect of different combi- 
nations of anti-tuberculous drugs 
(Completed study, 1992) 
To evaluate the early bactericidal activity (EBA) of different combinations of drugs 
with the drugs only after passing the cultures through a 0.45 µm membrane filter to 
remove the drugs and the medium and then resuspending the bacilli in fresh medium. 
Afterwards, the drugs will have to be added to the medium again in the required 
concentrations. This procedure of filtration and resuspension has been used in the 
earlier study on the EBA of RE and HZ on M.tuberculosis in Vitro (annual report 
1990) and has been found to result in gradual loss of bacilli over the duration of the 
experiment. In an attempt to avoid the loss of bacilli, a pilot experiment has been 
carried out after modifying the earlier method. In the earlier method, the medium from 
the cultures in universal containers was removed by filtration and the bacilli trapped 
on the filter membrane were recovered by resuspending them in fresh medium. In 
the modified method, the cultures are first centrifuged to deposit the bacilli. In the 
next step, the bacilli in the decanted supernatant are also recovered by filtration and 
concurrently compared with a third method along with two relevant control methods. 
In the third method, the cultures in 50ml sterile conical bottom centrifuge tubes are 
batch culture of M.tuberculosis H37Rv in duplicate aliquots was used for each of the 
five methods compared. The results are shown in Table 1. 
in in vitro system, viable counts will have to be set up from all the cultures treated 
resuspended along with the deposit. The earlier method and its modification have been 
centrifuged and only the deposits obtained are resuspended in fresh medium. A single 
From Table 1, it appears that the modified filtration method, although not showing 
an increase in the number of bacilli comparable to the controls, is better than the other 
methods in minimising the loss of bacilli. Hence, starting with M.tuberculosis H37Rv, 
the proposed study for the evaluation of bactericidal effect of ofloxacin in combination 
with R, E, H and Z in vitro will be carried out using the modified method. 
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Table 1 
Log cfu of M.tuberculosis H37Rv per ml medium in cultures 
treated with different methods for recovery of organisms 
***** 
Invitro activity of ciprofloxacin and ofloxacin on South Indian isolates of 
M.tuberculosis 
(Completed study, 1990-92) 
Resistance to rifampicin in strains of M.tuberculosis resistant to streptomycin 
and/or isoniazid indicates poor prognosis. For the treatment of such patients, sev- 
eral new classes of chemotherapeutic agents have been suggested. These include the 
aminoglycoside capreomycin, long-acting rifamycin derivatives, the 4-fluoroquinolones 
as well as beta-lactam antibiotics combined with betdactamase inhibitors (Allen & 
others, 1983; Mitchison and others, 1988). In Vitro studies with the long-acting ri- 
famycins, rifapentine and rifabutin as well as with capreomycin and ciprofloxacin were 
ciprofloxacin is poorly absorbed from the gastro-intestinal tract, and, therefore gives 
lower blood levels than norfloxacin and ofloxacin after oral administration. Further, 
ofloxacin has a longer terminal half-life in serum (67 hours). Ofloxacin is already 
being used in this centre on a selective basis for patients with multiple drug resistance. 
It was therefore proposed to test the activity of ofloxacin on South Indian isolates of 
M.tuberculosis in comparison with that of ciprofloxacin. 
presented in the 1989 report. Of these, ciprofloxacin was the most promising. However, 
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A total of 104 strains, comprising of equal numbers of SHR sensitive as well as 
SHR/HR resistant were tested. In addition, the standard sensitive strain, H37Rv 
was tested on different occasions. The drugs were incorporated in Lowenstein-Jensen 
standard suspension. The slopes were read after 28 days incubation and the minimal 
inhibitory concentrations (MIC) determined. 
medium in concentrations of 0.5, 1, 2, 4, 8, 16, 32 and 64 mg/l and inoculated with a 
The distribution of strains according to MIC for ciprofloxacin is presented in Table 
1. It is observed that the distributions were fairly similar, there being not much 
difference between sensitive and resistant populations. The geometric means of the 
MIC of sensitive and the resistant groups were 2.00 and 2.17 respectively. 
Strains 
H37Rv 
SHR sensitive 
SHR/HR resistant 
Total 
No. % strains with MIC of 
tested 0.5 1 2 4 8 16 32 64 
3 (l00) 1 
52 2 21 52 25 
52 2 7 67 23 
104 2 14 60 24 
1. Percentage based on small numbers is indicated in parentheses. 
Strains 
H37Rv 
SHR sensitive 
SHR/HR resistant 
Total 
No. 
tested 
% strains with MIC of 
0.5 1 2 4 8 16 32 64 
2 (100) 1 
52 2 15 63 19 
52 2 13 63 21 
104 2 14 63 20 
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Table 1 
Distribution of MIC of 
ciprofloxacin against South Indian isolates of M.tuberculosis 
Table 2 
Distribution of MIC of ofloxacin against 
South Indian isolates of M.tuberculosis 
The distrubution of MIC to ofloxacin is presented in Table 2. 
1. Percentage based on small numbers is indicated in parentheses. 
Here again there was no difference between the two catagories of strains in MIC, 
the geometric means of the sensitive and resistant populations being 2.00 and 2.05 
respectively. 
To conclude, both ciprofloxacin and ofloxacin had similar MICs for sensitive as 
well as resistant strains of M.tuberculosis. Also, there Was no cross-resistance between 
quinolones and streptomycin, isoniazid or rifampicin. 
***** 
Isolation of M.tuberculoais from cerebro spinal fluid(CSF) by filtration 
method - A pilot study. 
(Comp1eted study, 1992) 
Normally, the CSF specimen is centrifuged and the deposit inoculated for culture 
of AFB. As it is suspected that tubercle bacilli have the tendency to float up in the 
supernatant fluid during centrifugation, the rate of isolation of M.tubcrculosis by this 
If this is true, filtration of CSF through a filter membrane and processing of the 
membrane for culture can yield higher culture positivity. Hence, the objectives of the 
procedure could be affected to some extent by the loss of bacilli in the supernatant. 
present experiment were: 
1) to detect the presence of tubercle bacilli in the supernatant fluid and (2) to 
estimate rate of isolation of M.tuberculosis from CSF by a filtration method without 
resorting to centrifugation. 
CSF specimens (CSF): A total of 233 consecutive CSF specimens, obtained 
from as many children with suspected TBM, were investigated. Excess CSF, when 
available, was collected in a separate bottle (duplicate sample). The specimens were 
collected at the Institute of Child Health, Egmore, Madras and transported without 
delay to TRC, Madras where they were processed for culture of mycobacteria by the 
routine centrifugation method. 
Supernatant of CSF (S-CSF): The CSF specimen was centrifuged as a part of 
the centrifugation method and the supernatant fluid was separated. The supernatant 
fluid, available from 196 of the above specimens, was processed separately for culture 
by a filtration method described below and only these specimens were included in the 
analysis. The CSF from 37 patients were insufficient and the supernatant fluid was not 
available for filtration method. Of the 37 samples, 31, 4 and 2 were negative, positive 
and contaminated respectively, by the centrifugation method. 
Duplicate CSF specimens (D-CSF): A total of 112 duplicate CSF specimens, 
collected from as many of the above children, was processed for culture by the filtration 
method without resorting to centrifugation. 
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Filtration method: The S-CSF or the D-CSF was filtered, using a syringe, 
through a membrane filter (Pore size: 0.45 micron; diameter: 25mm; from Advanced 
Micro Devices Pvt.Ltd., Ambala, India) assembled in a filter holder (Laxbro, India). 
The membrane filter was then aseptically transferred to about 7 ml of selective kirch- 
ner’s liquid medium (SKLM) and incubated at 37°C. The SKLM bottles were examined 
weekly and centrifuged when the growth was suspected or at the end of 6 weeks, and 
their deposits subcultured onto LJ medium slopes. The LJ slopes were incubated, 
examined weekly, upto 8 weeks, and the growth of M.tuberculosis obtained was con- 
firmed by standard procedures followed in our laboratory. 
M.tuberculosis was isolated from 29 of 196 CSF specimens by the centrifugation 
method. The S-CSF from these specimens, processed by the filtration method, yielded 
11 isolates which included 2 additional positives. Thus, 9 (31%) aut of 29 culture 
positive specimens were found to contain tubercle bacilli in the S-CSF. This confirms 
the tendency of the tubercle bacilli to float up in the supernatant fluid during centrifu- 
gation. 
The culture results of the CSF and the D-CSF specimens from 112 children, pro- 
cessed by the centrifugation and the filtration method, respectively are presented in 
Table 1. 
Table 1 
Isolation of M.tuberculosis from CSF by filtration and 
centrifugation methods. 
The rate of isolation was similar by both the methods. Of 112 specimens, 11 were 
positive by centrifugation method and 13 by filtration method. Although valid conclu- 
sions can not be drawn as the CSF and D-CSF specimens were not randomly allocated 
to the two methods, they indicate that the filtration method can be employed as an 
alternative method for the isolation of M.tuberculosis from CSF without resorting to 
centrifugation. 
The filtration method is a simpler procedure compared to centrifugation method. 
It is less expensive, as it requires 1 SKLM and 2 LJ slopes when compared to 4 pairs 
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of 4 different media and an extra pair of LJ slopes required for subculture in the 
centrifugation method. As the filter holders with the membrane filters are available in 
sterile packs, the CSF obtained in Clinics/Hospitals can be filtered and the membranes 
transported, in SKLM, to a Central/Mycobacteriology laboratory for further culture 
work. 
In view of the practical advantages of the filtration method, there is a need for 
undertaking controlled investigation to confirm the findings of this pilot investigation. 
***** 
Isolation and species-level identification of non-tuberculous mycobacteria 
obtained from the environmental specimens of the BCG Trial area, Trivel- 
lore. 
(Completed study, 1991-92) 
Earlier studies in the South Indian BCG Trial area had shown that, in this popu- 
lation, the prevalence of infection with non-tuberculous mycobacteria (NTM) is very 
high. However, studies on the NTM in the environment of this area have not yet been 
done. 
The aim of this study was to isolate and identify the strains of NTM prevalent 
in the environment of the BCG Trial area, estimate the frequency of their occurrence 
and also to find out any seasonal variations in their occurrence. The environmental 
specimens included soil, water and house-dust. 
Two methods were chosen for processing each type of specimen: Engbaek’e method 
using 3% sodium lauryl sulphate (SLS) and 1% NaOH with inoculation on LJ and 
incubation at 30°C for soil and dust specimens, and Engel’s method using 3% SLS and 
1% NaOH with inoculation on LJ and incubation at 37°C for water specimens. 
Fifteen randomly selected villages in one panchayat union (Kadambathur) of the 
Trivellore taluk were chosen for the study. Ten specimens each of soil and water and 
5 specimens of dust were collected from each village. In addition, eight specimens of 
water were collected from the Poondi reservoir. All the specimens were collected over a 
period of one week and were brought to the Centre protected from light. The specimens 
were processed in lots over a period of three weeks. Specimens were collected on two 
occasions, once in January after the monsoons and once in June in summer. The same 
sites were sampled on both the occasions. 
All the isolates were subjected to preliminary identification testa to classify them 
according to Runyon’s groups. Detailed identification of the isolates up to species-level 
was done using 19 biochemical tests as described previously. 
Table 1 presents the culture results of the different environmental specimens. Of the 
specimens collected in January, 74.7% for soil specimens, 64.6% for water specimens 
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and 25.3% for dust specimens produced isolates of NTM, the corresponding figures for 
Type of Month of Total No. of 
specimen collection specimens 
specimens collected in June being 63.3% 41.3% and 18.7%, respectively. 
Table 1 
Number and percentage of exvironmental specimens 
yielding mycobacteria on culture 
Specimens with 
isolates of NTM 
No. % 
Soil 
Water 
Dust 
January 150 112 74.7 
June 150 95 63.3 
January 158 102 64.6 
June 109 45 41.3 
January 75 19 25.3 
June 75 14 18.7 
Soil specimens: A total of 161 isolates belonging to 12 species and 153 iso- 
lates belonging to 12 species were obtained from the soil specimens in January and 
June, respectively. The majority of the soil specimens yielded isolates belonging to the 
M.fortuitum complex (48.0% and 37.3% in January and June, respectively) followed 
by isolates belonging to the MAIS complex (16.7% in January and also in June). In 
the majority of cases,one or two species per specimen were obtained in both January 
and June. 
Water specimens: A total of 167 isolates belonging to 16 speciea and 57 isolates 
belonging to 11 species were obtained from the water specimens in January and June, 
respectively. The majority of the water specimens yielded isolates belonging to the 
MAIS complex (50.0% and 29.4% in January and June, respectively). Compared to 
the isolation profile of soil specimens, the percentage of specimens yielding isolates 
belonging to the M.fortuitum complex were few (3.2% and 2.8% in January and June, 
respectively). Most of the specimens yielded one or two species in both January and 
June. 
Dust specimens: A total of 22 isolates belonging to 5 species and 17 isolates 
belonging to 3 species were obtained from the dust specimens in January and June, 
respectively. The dust specimens predominantly yielded isolates belonging to the MAIS 
complex (13.3% and 17.3% in January and June, respectively) and the M.fortuitum 
complex (6.7% and 2.7% in January and Junei respectively). A maximum of 2 species 
per specimen was obtained in both January and June. 
Table 2 presents the species-level identification of the mycobacterial isolates ob- 
tained from the environmental specimens at the two time-points. 
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Table 2 
Number and percentage of environmental specimens yielding 
different mycobacterial species 
SPECIES 
RAPID GROWERS 
M. diernhoferi 
M. fortuitum 
M.gadium 
M.parafortuitum 
M.phlei 
M. smegmatis 
M.thermoresis- 
tibile 
M.vaccae 
Others 
SLOW GROWERS 
MAIS complex 
M. asiaticum 
M.flavescens 
M.gastri 
M.gordonae 
M. kansasii 
M. nonchromo- 
genicum 
M. szulgai 
M. terrae 
M. triviale 
M.xenopi 
Others 
Total no. 
of specimens 
SOIL 
Jan June 
5( 3.3 ) l( 0.7 ) 
1( 0.7 ) 0( 0.0 ) 
72( 48.0 ) 56( 37.3 ) 
11( 7.3 ) 22( 14.7 ) 
5( 3.3 ) 4( 2.7 ) 
6( 4.0 ) 5( 3.3 ) 
3( 2.0 ) 0( 0.0 ) 
5( 3.3 ) 4( 2.7 ) 
18( 12.0 ) 28( 18.7 ) 
25( 10.7 ) 25( 16.7 ) 
0( 0.0 ) 0( 0.0 ) 
l( 0.7 ) l( 0.7 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) l( 0.7 ) 
0( 0.0 ) l( 0.7 ) 
2( 1.3 ) 0( 0.0 ) 
0( 0.0 ) l( 0.7 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
l( 0.7 ) l( 0.7 ) 
6( 4.0 ) 3( 2.0 ) 
150 150 
WATER 
Jan June 
13( 8.2 ) 2( 1.8 ) 
5( 3.2 ) 3( 2.8 ) 
6( 3.8 ) 1( 0.9 ) 
0( 0.0 ) 0( 0.0 ) 
1( 0.6 ) l( 0.9 ) 
0( 0.0 ) 0( 0.0 ) 
5( 3.2 ) 2( 1.8 ) 
8( 5.1 ) 3( 2.8 ) 
2( 1.3 ) 3( 2.8 ) 
79( 50.0 ) 32 ( 29.4 ) 
4( 2.5 ) 0( 0.0 ) 
l( 0.6 ) 0( 0.0 ) 
6( 3.8 ) 2( 1.8 ) 
4( 2.5 ) l( 0.9 ) 
0( 0.0 ) 0( 0.0 ) 
7( 4.4 ) 0( 0.0 ) 
2( 1.3 ) 3( 2.8 ) 
12( 7.6 ) 2 ( 1.8 ) 
l( 0.6 ) 0( 0.0 ) 
11( 7.0 ) 2( 1.8 ) 
0( 0.0 ) 0( 0.0 ) 
158 109 
DUST 
Jan June 
l( 1.3 ) 0( 0.0 ) 
5( 6.7 ) 2( 2.7 ) 
0( 0.0 ) l( 1.3 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
l( 1.3 ) l( 1.3 ) 
10( 13.3 ) 13( 17.3 ) 
l( 1.3 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
0( 0.0 ) 0( 0.0 ) 
l( 1.3 ) 0( 0.0 ) 
3( 4.0 ) 0( 0.0 ) 
75 75 
Table 3 presents the distribution of specimens according to the number of species 
obtained. 
63 
Table 3 
Distribution of specimens positive for mycobacteria 
The isolation profile of mycobacteria from water specimens indicates a predomi- 
nance of MAIS complex organisms. Isolates belonging to M.asiaticum, M.gordonae , 
and M.triviale were also obtained only from water specimens. In contrast, there was a 
number of isolates was low for dust specimens, the majority of these specimen yielded 
isolates belonging to the MAIS complex, as was seen for water specimens. 
predominance of M.fortuitum complex organisms in soil specimens. Though the total 
Control soil specimens: A limited number (10) of soil specimens from Eng- 
land collected in January 1992 were also studied. The 21 mycobacterial isolates from 
these specimens belonged to 5 species, namely, M. bovis, M. diernhoferi, M.flavescens, 
M.gastri and M.smegmatis. No isolates belonging to either the MAIS complex or the 
M. fortuitum complex were obtained. 
***** 
Restriction fragment length polymorphism (RFLP) analysis of M.tuberculosis 
isolates from South India 
(Completed study, 1992) 
,In this study, RFLP analysis has been used as a strain specific marker (1) to 
match the pretreatment isolates with the isolates at the time of relapse in patients 
who relapsed after short course chemotherapy and also (2) to study the differences in 
RFLP patterns in pretreatment (PT) isolates of M.tubcrculosis from South Indian 
patients. For this RFLP analysis, we have used a probe, an Insertion sequence-IS 986 
which is found to be specific for M.tuberculosis complex. 
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according to the number of species obtained per specimen 
Two isolates were obtained, one as pretreatment (PT) and the other as relapse 
culture (R), from each of the 71 patients who relapsed and were coded to conceal their 
identity. DNA was prepared and analysed from mycobacterial isolates according to the 
protocol of Hermans et al. (J.Clin. Microbiol. 1990, 28, 2051). In brief, 3-4 week old 
cultures grown on 7H9 medium were used for DNA extraction. It was digested with Pvu 
II,subjected to electrophoresis in 1% agarose gel and blotted onto Hybond-N membrane 
filter. DNA blots were hybridized to the PCR amplified 386 base pair,Xho I-BamH I 
fragment of IS 986 which was labelled for detection by enhanced chemiluminescence 
(ECL-Amersham) technique. The molecular sizes of the relevant DNA fragments of 
mycobacterial isolates were determined from the internal DNA standards size marker 
(Lambda - Hind III digest). 
After decoding, how many individual patients had been idenfified as having the 
same RFLP pattern was assessed. Out of 71 patients, for 6 patients either pretreatment 
(PT) or relapse (R) cultures were contaminated. Of the 65 Comparisons of pretreatment 
with relapse cultures, only 11 (17%) were found to be same. Remaining 54 patients’ 
cultures, either showed no band, a single band pattern or different RFLP patterns, and 
hence they could not be matched. Among them, totally 13 cultures did not show any 
IS 986 copy while 47 cultures showed a single copy of IS 986. Other genetic markers 
will be used to distinguish strains which have shown either none, one or low number 
of copies with IS 986, before concluding the relatedness of strains. 
To study the diversity of RFLP patterns among South Indian isolates, we separately 
analysed 98 pretreatment cultures (68 PT from relapse group + additional 30 PT 
cultures). In this analysis, 39 cultures again showed a single copy of IS 986 in the region 
of approximately 1 kb fragment. It will be of interest to identify and characterize the 
strains with single band pattern. 
Overall, the isolates from 98 patients showed 51 distinct finger prints which is less 
polymorphic when compared to strains from other countries. 
***** 
Evaluation of anti-body level to PPD by ELISA for identification of tuber- 
culous infection 
(Completed study, 1992) 
The tuberculin skin. test with purified protein derivative (PPD), has been the tradi- 
tional method for identification of tuberculous infection. But, it is known that the skin 
test is not absolutely specific, since non-specific cross reactivity to other mycobacteria 
can also lead to positivity. Also, the test is not 100% sensitive, since a proportion of 
persons with the disease (and therefore definitely infected) show false negativity due 
to various causes. Further, the skin test has several practical disadvantages like need 
for well trained field workers for ita administration and reading its reactions. The 
test cannot also be repeated under the same conditions as its carry-over effect has 
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been well documented. Therefore, there is need for a serologic test for identification of 
tuberculous infect ion. 
The objective of the present investigation is to evaluate the role of antibody level to 
PPD by ELISA for identifying tuberculous infection. The rationale of the investigation 
consists in identifying two groups of subjects, namely 
(i) definitely infected with M. tuberculosis and 
(ii) definitely not infected with M.tuberculosis and evolving a criterion for 
tuberculous infection on the basis of the distribution of antibody levels in 
the two groups. 
While sputum positive tuberculosis cases can be easily identified as a definitely 
infected group, the uninfected group can be identified only approximately. Nine months 
to fifteen months old children without any contact history of tuberculosis in the family 
or in the neighbourhood may provide the closest group for the uninfected. The reason 
for omission of children below nine months is the possibility that such children might 
be possessing maternal antibodies. But for practical reasons, children aged 1-3 years 
with Mantoux reaction (0 - 7 mm) to tuberculin skin test are considered as uninfected 
group in this investigation, as tuberculin surveys revealed low infection rates in that 
age group. 
Description of study population: A total of 632 finger-prick specimens, were 
collected during 1992 from the following categories of subjects from Trivellore BCG 
Trial area. The Mantoux tests were done with 1 TU of RT23 within 6 months prior to 
collection of finger prick-specimens. 
Category A: Children aged 1-9 years with Mantoux induration of 0 to 12 
mm to PPD. 
Category B: Children aged 1-9 years with Mantoux induration of 16 mm 
or more to PPD. 
Category C: Tuberculosis cases (bacteriologically confirmed). 
Category D: Adults aged 15-24 years with Mantoux induration of 0 to 12 
mm to PPD. 
Category E: Adults aged 15 - 24 years with Mantoux induration of 16 
mm or more to PPD. 
Assay design: The samples were tested at a dilution of 1 : 100. The specimens 
within each category were randomly and proportionately divided into group of 40 
specimens each to be assayed in 16 different ELISA plates. In addition to the above 
632 specimens, 8 specimens were assayed in each of the 16 ELISA plates as standards. 
These 8 standards consisted of 3 buffers, sera from 3 sputum positive pulmonary tu- 
berculosis patients and sera from 2 healthy subjects. Thus a total of 640 specimens 
were assayed with 3 different antigens. PPD (PPD-S, 288 and 289), culture filtrate 
66 
of M.tuberculosis and culture filtrate of M.scrofulaceum. The antigen was coated to 
the plates at a concentration of 5 µg/ml. Forty test specimens and 8 standards to be 
assayed in a plate were randomly allocated to different wells within the plate and were 
also coded to conceal the identity of the specimens. 
Exclusions: All the specimens in one ELISA plate (because of a processing error) 
and all specimens obtained from subjects with BCG scars were excluded from analysis. 
Analysis of experimental errors: Each specimen was assayed in 2 consecutive 
wells in each plate. While the standard deviation (with 48 degrees of freedom) of within 
plate replicate variation ranged from 0.09 - 0.12 among the 3 antigens, the standard 
deviation of between plate variation ranged from 0.14 - 0.42 among the 5 standard 
specimens assayed in each of the 15 plates. In spite of the differences that occurred in 
setting up the assays on different days and in different plates, it is possible to validly 
compare the optical density(O.D.) distributions of one category with that of another, 
in view of the design adopted for the assays. 
Results: It was found that the O.D. values to any two antigens were positively 
correlated and the values of correlation of coefficient ranged from 0.7 to 0.9. Therefore, 
the analysis is confined to O.D. values to PPD only. Table 1 provides the percentage 
frequency distributions of six groups of subjects. The descriptions of the groups are 
given in the foot note to Table 1. 
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Table 1 
Percentage frequency distributions according to 
Description of groups: 
A1 : Children aged 1-3 years with induration of 0-7 mm 
C : Bacteriologically positive tuberculous cases 
A2 : Children aged 4-9 years with induration of 0-7 mm 
B2 : Children aged 4-9 years with induration of 16 mm or more 
D : Adults aged 15-24 years with induration of 0-12 mm 
E : Adults aged 15-24 years with induration of 16 mm or more. 
Discriminant analysis (using BMDP package) was carried out between children 
aged 1-3 years with Mantoux induration of 0 to 7 mm as uninfected group (A1) and 
bacteriologically positive tuberculosis cases (C) as infected group to arrive at a cut-off 
O.D. value to classify subjects into ELISA positives and ELISA negatives to indi- 
cate infection and non-infection respectively. The cut-off O.D. value was found to be 
1.262,i.e., any subject with a O.D. of 1.262 or higher is classified as ELISA positive 
and otherwise as ELISA negative. The results of application of this cut-off O.D. value 
in the two groups used in the Discriminant analysis are shown in Table 2. 
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OD value to PPD in different groups of subjects 
Size of Mantoux 
Group induration (mm) 
0-7 
Tuberculous 
patients 
ELISA 
No. % No. % 
25 78 7 22 32 
Positive Negative Total No. 
8 - 12 
> 12 
3 60 2 40 5 
52 71 21 29 73 
It is seen (Table 2) that 58 of 73 children are classified as ELISA negative cor- 
responding to a specificity of 79%. It is also seen that 80 of 110 definite cases of 
tuberculosis were classified as ELISA positive, corresponding to a sensitivity of 73%. 
Both these expected values of specificity and sensitivity for identifying tuberculous 
infection are not satisfactory. 
Since assays were undertaken independently and concurrently in the other group 
of subjects, they were classified on the basis of the cut-off O.D. value and tabulated 
according to age and Mantoux induration in Table 3. 
Children 
aged 1-3 yrs 
Subtotal 80 73 30 27 110 
0-7 15 21 58 79 73 
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Table 2 
ELISA Positivity in the two groups used 
for Discriminant analysis 
Table 3 
ELISA positivity in different groups of 
It is generally accepted that an induration of 16 mm or more to the standard tu- 
berculin test is a stringent criterion and definitely indicates past tuberculous infection. 
It is therefore surprising to find that high percentages of such subjects are classified as 
ELISA negatives; 52% in 49 year age group and 40% in 15-24 age group with indura- 
tion of 16 mm or more are classified as ELISA negatives. On the other hand, a great 
majority of subjects with Mantoux induration of 0-7 mm are likely to be uninfected. 
In such subjects, it is found that 50% in 4-9 age group and 56% in 15-24 age group 
are ELISA positive. Therefore, in view of the low expected and observed values of 
sensitivity and specificity, it is concluded that antibody level to PPD has no role in 
determining the tuberculous infection. 
***** 
Histopathological classification of tuberculous lymphadenitis 
(Completed study, 1988-92) 
The aims, objectives and the methodology of this study have been described in 
1989 annual report. 
A total of 352 patients remained in the study, after exclusions. 
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subjects by age and Mantoux induration 
The major findings of this study are as follows : 
1. The cases of tuberculous lymphadenitis are classified into four types : non- 
reactive, hyporeactive, reactive and hyperplastic. The description of these types 
has been given in detail in the 1989 annual report. There is a histological spec- 
trum of responses ranging from a poor responding granuloma with necrosis to 
a good response with virtually no tissue destruction. The two extreme types 
form only about one third of the total cases and the remaining types exhibit a 
moderate response with varying amounts of tissue destruction. 
2. The presence of B-cells, plasma cells and complement C3d in the lesions of most 
of these histological types indicate the possibility of the participation of humoral 
immune response in the genesis of these lesions. 
3. Clinically, there are no major differences in the child population, but, amongst 
the adults where nearly three fourths were females, the following was observed; 
while the male to female ratio was 1:3 or 4 in the non reactive, hyporeactive and 
reactive types, it was nearly 1 : 1.5 in the hyperplastic variety. Also, the males 
belonging to this category had lower Mantoux reaction than the other groups 
4. There were no major differences in the bacteriological features of the cases be- 
longing to different types. 
***** 
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LABORATORY STUDIES - IN PROGRESS 
Beta Lactamase activity in mycobacteria and its possible role in cefadroxil 
resistance 
(Ongoing study, 1991-93) 
An investigation was undertaken to know the susceptibility of NTM to cefadroxil 
(See 1991 annual report). All the 40 isolates tested were not susceptible to cefadroxil 
even at 40 mg/l which is much higher than the peak plasma level (28 mg/l) attained 
in human beings . 
Since Beta lactamase plays an important role in Beta Lactam resistance, a quali- 
tative test (ARRD, 1966,94,965) to detect its activity has been standardised in order 
to understand its role in cefadroxil resistance in mycobacteria. The NTM isolates 
mentioned above and the clinical isolates of M.tuberculosis (annual report, 1991) are 
being tested for their Beta lactamase activity. 
***** 
Shortening the duration of susceptibility tests of M.tuberculosis strains by 
bioluminescence assay 
(Ongoing study, 1990-93) 
Bioluminescence assay of Adenosine triphosphate (ATP) is an useful method for 
estimation of viable mycobacteria, and unlike conventional method, the results can be 
obtained within a short period of time. ATP content of viable bacilli is constant and is 
proportional to colony forming units. This assay has been found to be useful in rapid 
susceptibility testing of M.tuberculosis cultures to various drugs such as Streptomycin 
(S), Isoniazid (H), Rifampicin (R) and Ethambutol (E), (Nilsson et al, 1988; Beckers et 
al 1985). In the present study also, this assay was used for drug susceptibility testing 
of M.tuberculosis to S, H, R & E. 
Middlebrook 7H9 broth containing S, H, R & E was prepared and distributed in 
1 ml quantities. Single colony growth of cultures in 7H9 medium containing approxi- 
mately 104 organisms/ml was inoculated into plain and drug containing 7H9 medium. 
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ATP assay was done at the end of 5 days of incubation at 37° C after releasing ATP by 
Nucleotide releasing agent for bacteria (NRB) and relative light units (RLU) were esti- 
mated. Using standard inoculum of the same single colony growth, drug susceptibility 
testing to S, H, R & E was done by conventional method. 
The mycobacterial ATP level was calculated as the percentage of the ATP level in 
an unexposed control culture (ATP index). The discriminating concentration (break 
point) for S and E was 1 mcg/ml and, for R and H, it was 0.1 mcg/ml (Beckers et al, 
1985). Similar discriminating concentration was used for S and E in the present study. 
For R and H, the break points were 0.5 mcg/ml and 10 mcg/ml respectively which 
showed better agreement. ATP index had to be less than 1 to classify the strain as 
sensitive. Culture having an ATP index of 1 or more is taken as resistant. 
The crude agreement between ATP assay and conventional method with regard to 
S susceptibility was 83%. For E, R and H, crude agreements of 74%, 72% and 68% 
were observed respectively. After correcting for agreement due to chance, moderate 
agreement was observed only for streptomycin and isoniazid ( k = 0.61) and not for 
other drugs. 
Using a different ATP extraction method involving boiling TRIS-EDTA, the as- 
say was repeated for 16 cultures. The results by the TRIS method showed better 
correlation with the conventional method compared to NRB method. 
In order to improve this method, it is proposed to test another 40 M.tuberculosis 
cultures by both ATP assay using TRIS method and by conventional method with 
standard inoculum and also with inoculum containing 104 organisms/ml. Sensitivity 
testing will be done with 0.1 mcg, 1 mcg and 10 mcg/ml for all the four drugs. 
The study is to be continued further. 
***** 
Investigation of clones of M.tuberculosis isolated from primary cultures of 
patients for their phenotypic/genotypic differences: A pilot investigation. 
(Ongoing study, 1992-93) 
It is very well known that pulmonary tuberculosis is caused by the inhalation of 
tubercle bacilli in the aerosols. The aerosols could get eliminated by the natural process 
or get deposited in the apical-subapical region of the lung to give rise to disease either 
immediately or afterwards, This exposure to aerosols is likely to be multiple and 
different subtypes (Phage types, Biotypes, Genotypes) of the organism in different 
sites or at the same site at different time points, is likely to occur. If this is true, and 
if all the implants or at least few of the implants multiply to produce disease at the 
larger in an endemic area. In such a situation, the implantation of aerosols containing 
73 
same time, then significantly large proportion of patients are likely to harbour different 
types of the organism. Hence it will be of interest to demonstrate different subtypes of 
the organism in the primary isolates from pulmonary tuberculosis patients by studying 
the clones for their phenotypic/genotypic characters. 
To initiate the investigation, 12 primary cultures with atleast 2 plus growth on LJ 
slopes, obtained from as many pulmonary tuberculosis patients, were selected. A scoop 
of the inoculum, representative of the entire culture, was suspended in about 7ml of 
7H9 liquid medium and homogenised. Then it was filtered through a filter membrane 
(Pore size: 5.0 micron; diameter: 25mm; from Advanced Micro Devices Pvt. Ltd., 
Ambala, India) and the filtrate was divided into 3 aliquots of about 2 mil each and 
stored at - 70°C. Ten fold dilutions of one of the aliquots were made, before storage, 
and plated onto plain 7H11 agar medium to get individual colonies. The plates were 
incubated at 37°C in a CO2 incubator for 3 weeks. From these plates, 10 individual 
colonies, picked up arbitrarily, were subcultured separately onto 7H9 liquid medium. 
The 7H9 culture was divided into 2 aliquots and stored at- 70°C for further studies. 
This study is in progress to know the RFLP pattern of the clones of these primary 
isolates. RFLP pattern will be analysed for these 100 clones and further experiments 
will be planned subsequently. 
***** 
Characterization of MAIS complex isolates and M.fortuitum complex iso- 
lates in clinical and environmental specimens from the BCG trial area. 
(Ongoing study, 1992 - 93) 
In the study carried out to find out the prevalence of NTM in the environment of 
the BCG Trial area, organisms belonging to the MAIS complex and the M.fortuitum 
complex were among the most frequently isolated organisms from the different types of 
specimens. In all, a total of 143 isolates belonging to the M.fortuitum complex and 184 
isolates belonging to the MAIS complex were obtained from environmental specimens 
in that study. In addition, 23 isolates belonging to the M.fortuitum complex and 138 
isolates belonging to the MAIS complex were obtained from subjects in the study area 
during the same time-points. 
Studies are in progress to characterize the isolates belonging to these two complexes 
up to species, subspecies and biovariant levels based on drug susceptibility patterns, 
resistance to heavy metals, gas-liquid chromatography and plasmid profiles. Studies 
done elsewhere have shown that these methods are useful in differentiating between 
clinical and environmental isolates belonging to these species. 
***** 
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Immune response in the guinea pig model to M.avium-intracellulare (MAI) 
and M.fortuitum complex isolates from clinical specimens and environment 
(Ongoing study, 1992-93) 
It is proposed to study the immune response to selected MAI and M.fortuitum 
ments. The study has been started using MAI complex isolates. The design of the 
experiment is given in Table 1. 
complex isolates from environmental and clinical specimens in animal model experi- 
Table 1 
Time 
(Weeks) 
0 
6 
11 
12 
14 
18 
24 
Group 1 
Control 
ST 
SIV 
Score 
VC 
Score 
VC 
Score 
VC 
Group 2 
B C G - S I V 
BCG 
ST 
SIV 
Score 
VC 
Score 
VC 
Score 
VC 
Design of the experiment1 
Group 3 
MAI-BCG-SIV 
MAI 
BCG 
ST 
SIV 
Score 
VC 
Score 
VC 
Score 
VC 
Group 4 
MAIE-BCG-SIV 
MAIE 
BCG 
ST 
SIV 
Score 
VC 
Score 
VC 
Score 
VC 
Group 5 
MAIC-BCG-SIV 
MAIC 
BCG 
ST 
SIV 
Score 
VC 
Score 
VC 
Score 
VC 
1. Five animals in each group are sacrificed at 14, 18 and 24 weeks 
MAI, MAIE and MAIC indicate standard strain, environmental isolate and 
clinical isolate of MAI respectively 
SN : M.tubcrculosis South Indian low virulent strain (N9431) 
ST : Skin tests using PPD-RT 23 and PPD-B 
Score : Scores for extent of disease;VC: Viable count in spleen 
A total of 75 guinea pigs were taken and divided into five groups, with 15 in each. 
Group 1 is the control group. Groups 3,4 and 5 were sensitized with a standard strain, 
an environmental isolate and a clinical isolate of MAI, respectively. Six weeks later the 
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animals in groups 2,3,4 and 5 were immunized with an ID injection of BCG. In the fifth 
week after immunization, all the animals were skin-tested simultaneously with PPD- 
RT 23 and PPD-B. Six weeks after immunization all the animals were challenged with 
an IM injection of a South Indian Low Virulent (SILV) strain of M.tuberculosis . From 
each group, five animals will be sacrificed at 2,6 and 12 weeks after challenge. Scores 
will be given for the extent of infection in the lungs, liver, spleen and lymph nodes, 
and spleen viable counts will be set up. On the completion of this animal experiment, 
the immune response to the MAI isolates from various sources will be compared on 
the basis of skin-test reactivity, scores and spleen viable counts. A similar experiment 
is planned using M.fortuitum complex isolates. 
***** 
Pharmacokinetics of rifampicin, ethambutol, isoniazid and pyrazinamide 
following administration of the drugs individually or in different combina- 
tions in healthy subjects 
(Ongoing study, 1992-93) 
Rifampicin (R), ethambutol (E), isoniazid (H) and pyrazinamide (Z) are commonly 
used drugs in the treatment of tuberculosis. Only limited information is available on 
the pharmacokinetic interactions between these drugs. It is therefore proposed to 
undertake an investigation to obtain information on the plasma concentrations and 
the urinary excretion of these drugs together with their primary metabolites when 
administered alone or in various combinations. 
An innovative approach to the chemotherapy of tuberculosis has been the intro- 
duction at our Centre of the use of 2 different double-drug combinations on alternate 
days thus making each 2-drug combination intermittent. This approach will reduce 
the bulk of drugs to be consumed by the patient daily and the incidence of adverse 
reactions is expected to be appreciably less. Recent investigations invitro and in ex- 
perimental tuberculosis of the mouse have shown that the double-drug combinations 
of RZ and RE are superior to RH and REHZ in their bactericidal effect. The decrease 
in the effect of RH and REHZ combinations has been attributed to an antagonism 
between rifampicin and isoniazid and also to a possible decrease in the bioavailability 
of rifampicin leading to lower plasma levels of the drug when administered together 
with isoniazid. This latter phenomenon is yet to be demonstrated in human subjects 
and it is therefore desirable to obtain information of the plasma levels of rifampicin 
when administered alone and in combination with E, H, Z or EHZ. 
These investigations are being undertaken in a total of 17 healthy subjects (volun- 
teers) with normal hepatic and renal function. Each volunteer will be investigated on 
4 occasions with an interval of one week between occasions according to the general 
design given in Table 1. 
The volunteers will be randomly allocated to the different treatment groups (rows) 
as given above. A cross-over design will be employed and the drugs or their com- 
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binations to be administered to the individual volunteers on the different occasions 
(columns) will also be random. On each occasion, about half the volunteers will re- 
ceive rifampicin or a combination containing the drug (the first 8 serial Nos.) Plasma 
concentrations of the drugs administered will be determined at 1, 2, 3, 6, 9 and 12 
hours; further, excretion of the drugs and their primary metabolites in urine excreted 
over a 12-hour period will also be determined on each of the 4 occasions. By adopting 
the design given above, information on plasma levels and urinary excretion will be 
available on 8 volunteers on rifampicin alone and on 6 each with the other drugs and 
combinations. 
Sl. 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Table 1 
Design of the investigation 
I 
R 
R 
R 
R 
R 
R 
R 
R 
Z 
Z 
Z 
Z 
Z 
Z 
E 
E 
E 
Occasion 
II 
RH 
RH 
RH 
RH 
RH 
RH 
RZ 
RZ 
H 
H 
H 
E 
E 
E 
H 
H 
H 
III 
RZ 
RZ 
RZ 
RZ 
RE 
RE 
RE 
RE 
ZH 
ZH 
ZH 
ZE 
ZE 
ZE 
EH 
EH 
EH 
IV 
RE 
RE 
REHZ 
REHZ 
REHZ 
REHZ 
REHZ 
REHZ 
ZE 
ZE 
ZE 
EH 
EH 
EH 
ZH 
ZH 
ZH 
R: Rifampicin; E Ethambutol; H: Isoniazid; Z: Pyrasinamide 
The dosages of the drugs to be investigated will be approximately 10 mg/kg body- 
weight for rifampicin, 25 mg/kg for ethambutol, 12 mg/kg for isoniazid and 35 mg/kg 
for pyrazinamide. 
The interactions between the drugs will be studied on the basis of the mean peak 
concentrations, area under the time concentration curve and half-life of the drug in 
plasma and on the renal clearance of the drugs. 
The study is in progress and the results are being analysed. 
***** 
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Characterization and purification of antigenic components of M.tuberculosis 
(Ongoing study , 1988-93) 
Isolation of mycobacterial antigen(s) using affinity chromatography was described 
in the 1991 annual report. It was reported that the yields of these antigens were quite 
low and also the antigens were not useful for diagnosis. Hence other methods are being 
tried for isolation of relevant antigen(s) from M.tuberculosis . It was decided to use 
preparative Isoelectric Focussing (IEF) for isolation and purification of antigens. Since 
it has been planned to use 5 g of M.tuberculosis antigens in IEF, efforts have been 
made to prepare large quantities of these antigens. 
Methods of preparation of antigens: The selected M.tuberculosis strain was 
grown in Sauton’s medium for 68 weeks. The culture supernatant was removed by 
centrifugation at 6000 rpm for 30 minutes and sterilized by filtration through Seitz 
filter. The filtrate was precipitated using 80% ammonium sulphate saturation , dis- 
solved and dialysed extensively against phosphate buffered saline (PBS). The dialysate 
was termed culture filtrate antigen (CF). Pelleted bacilli were washed thrice in PBS 
5 minutes in cold. The sonicate was passed through a French Pressure cell (20000 
psi), centrifuged at 6000 rpm for 30 minutes and the supernatant was used as Pressate 
antigen. 
with Tween 80 , suspended in PBS containing protease inhibitors and sonicated for 
Large quantities (approximately 2 g) of these antigens have been prepared for two 
C which will strains (H37Rv and South Indians low virulent) and kept frozen at -20º 
be purified by preparative Isoelectric Focussing. 
Further work is in progress. 
***** 
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Development of DNA probes for M.tuberculosis 
(Ongoing study, 1988-93) 
In 1991 annual report, the isolation and characterization of pTRC4 was reported. 
pTRC4 is a circular plasmid with a mycobacterial fragment (2.2 kb) in pGEM4 plasmid 
promising, it was decided to continue the work with pTRC4. 
vector. Since the previous results obtained on RFLP and specificity experiments were 
This year, we report the complete sequence of this fragment. The sequencing was 
done as follows. The clone, pTRC4, has Sp6 polymerase primer on one side of the 
mycobacterial insert and T7 polymerase primer on the other side of the insert. Using 
these two primers, short stretch of the clone was sequenced. From this short stretch of 
sequence, oligonucleotides were designed and were used for further sequencing. Thus 
by designing various oligonucleotide primers, the whale length of the pTRC4 clone has 
been deduced. Subsequently, pTRC4 clone was subcloned into pP4 and pEP4. The 
fragments, PST 1 - PST 1 from pP4 and ECOR 1 -PST 1 from pEP4, were sequenced. 
Thus the original sequence of pTRC4 was confirmed. The deduced sequence is shown 
in Table 1. The interesting features of the sequence are: 
(1) It has 6 inverted repeats (14 base pairs long with 2 mismatches) occur- 
ring at bases (a) 5 and 1804, (b) 29 and 1823, (c) 466 and 1136 and (d) 
520 and 544 (e) 911 and 1560, and (f) 968 and 1217. 
(2) It has 4 direct repeats which are given in brackets in bold face. 
(3) A long palindrome is also located just before the putative open reading 
frame (1031). 
(4) It has more than one open reading frame. It will be interesting to know 
whether this clone is an insertion element. 
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From this sequence, several PCR primers will be designed. These primers will be 
evaluated for their usefulness in diagnosis. 
***** 
Human leucocyte antigen (HLA) studies in tuberculosis 
(Ongoing study, 1990-95) 
The main objective of the project is to use a combination of serological and DNA 
probes to analyse the phenotype and the genotype of a number of individuals to find 
out whether there exists an association between any serological and/or DNA marker 
and the occurrence of tuberculosis. 
HLA-phenotyping and genotyping will be carried out by HLA-antisera and HLA- 
gene probes, respectively. The progress of the studies is reported under four different 
sections. 
***** 
I. HLA studies - Screening of parous women sera for HLA-DR and DQ 
anti-bodies 
(Completed study, 1992) 
To add to the existing HLA-A, B, C, DR and DQ antisera, attempts were made to 
procure more HLA-DR and -DQ antisera during the year. 
It has been established that the sera of pregnant women are the most suitable and 
easily obtainable source for HLA antibodies. Further, it is known that HLA-A, -B and 
-C antisera contain frequently anti-HLA-DR and -DQ antibodies. 
A total of 52 HLA-A and -B positive sera of South Indian parous women obtained 
by Tamil Nadu Forensic Science Laboratory, Madras were screened for the presence of 
the HLA-A, -B and -C antibodies in a micro-method and screened against HLA-DR 
sera screened, 20 were found to contain HLA-DR and -DQ antibodies. The behaviour 
or the reaction patterns of these 20 sera were analysed. The ‘correlation coefficient’ (r) 
of a given serum with an antigen was calculated using 2 x 2 contingency table using 
the formula given below: 
HLA-DR and -DQ antibodies. The sera were absorbed with pooled platelets to remove 
and -DQ typed B-lymphocyte panel (30 staff members of Forensic Science Lab.). Of 52 
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r = (ad - bc) / Ö( a + b)(a + c)(c + d)(b + d) 
where a, b, c and d represent frequencies in 2 x 2 table with following definitions: 
a = The Positive (antigen positive/serum positive) 
b = False Positive (antigen negative/serum positive) 
c = False Negative (antigen positive/serum negative) 
d = True Negative (antigen negative/serum negative) 
Of the 20 positive sera, 7 sera were found to be specific for well-defined DR and 
DQ antigens and the remaining 13 sera were multispecific, reacting with more than 
2 HLA-DR and -DQ antigens. Table 1 represents the serum reaction pattern of 7 
HLA-DR and -DQ positive sera. Only the first 5 sera (1 to 5) are taken for HLA-DR 
and -DQ typing, as the r-values of the other two sera (CDM 1501 and CDM 1593) are 
very low. 
1. parous women screened against a panel of 30 HLA typed B-lymphocytes 
***** 
II. HLA studies - HLA distribution in population in Madras and its suburbs 
(Completed study, 1992) 
A total of 113 healthy subjects (mainly from city colleges and staff of Forensic Sci- 
ence Laboratory,) living in Madras city and its suburbs were investigated to know the 
Class-I (HLA, -A, -B, -C) and Class-II (HLA-DR, -DQ) antigen and gene frequencies 
in South Indian population. Fifty two individuals were HLA-typed in Tuberculosis 
Research Centre and 61 individuals were HLA-typed at Forensic Science Laboratory. 
The phenotype and genotype frequencies of majority of the class-I and class-II antigens 
were similar to that of North Indian population and Caucasoid population (Table 2). 
However an increased gene frequency of HLA A2, B17, DR 7, DRW8, DRW10 and a 
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Table 1 
Serum behaviour of the seven HLA-DR and DQ positive sera1 
decreased frequency of B12, BW35, CW4 and DR 1 antigens were seen in the Madras 
city population (and its suburbs) than the North Indian population. 
Table 2 
Comparison of percent gene frequencies1 of selected 
HLA-class I and class XI antigens from relevant investigations 
Present South Indian2 North Indian3 European4 
A2 
B12 
B17 
BW35 
cw4 
CW6 
DR 1 
DR 2 
DR 3 
DR 7 
DRW 8 
DRW 10 
study Caucasian 
20.7 16.4 11.9 26.0 
5.5 5.3 9.0 12.1 
12.0 10.1 7.8 4.2 
8.8 10.3 14.5 9.5 
14.3 22.5 8.9 22.1 
17.5 13.2 1.8 15.1 
4.1 3 .0 7.3 6.9 
27.7 25.7 27.2 13.4 
9.3 5.3 14.0 10.8 
20.7 15.4 11.9 12.5 
5.7 6.1 0.4 2.7 
7.4 7.0 1.1 0.7 
1. Percent gene frequency is calculated using the following formula. Gene fre- 
quency = 1 - Ö 1 - PF ; where PF = Phenotype or antigen frequency 
2. Pitchappan et al., 1984; and 1989 ; 
3. Mehra et al., 1986; 
4. Baur & Danilous, 1980. 
**** 
III. HLA studies - HLA and Immune response 
(Ongoing study, 1990-95) 
During the year, HLA-A, -B, -DR and-DQ serological typing was carried out in 11 
volunteers (TRC-laboratory) in addition to the 40 volunteers mentioned in 1991 annual 
report. It is well established that the HLA-Class-II antigens (HLA-DR, -DQ and -DP) 
are known as Ia antigens (Immune region associated antigens) and their genes as Ir 
genes (Immune response genes). The role of HLA Class-II antigens and their genes 
will be studied in the laboratory volunteers and tuberculosis patients. 
on the antibody and cell mediated immune responses against M.tuberculosis antigens 
***** 
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N. HLA studies-Investigation in quiescent and relapse cases of pulmonary 
tuberculosis 
(Ongoing study, 1992-94) 
An exploratory study was undertaken to find out whether there is any association 
between HLA-antigen or haplotype and the occurrence of relapse of tuberculosis in 
successfully treated pulmonary tuberculosis patients. A total of 100 quiescent patienta 
and 100 relapse patients will be investigated. 
During the year, serological determination of HLA-A, -B, -DR and -DQ antigen 
was carried out in 9 quiescent and 9 relapse cases of pulmonary tuberculosis. DNA 
were extracted from the peripheral blood white cells of these patients and stored at 
-70° C. The DNA will be later used for HLA-genotyping and tumor necrosis factor and 
T-cell receptor gene polymorphism. 
The study is in progress. 
***** 
Use of monoclonal antibodies for antigen detection assays. 
(Ongoing study, 1990-95) 
The mouse monoclonal antibody 31.3 which was found to be useful in antigen de- 
tection assay is being used in affinity chromatography procedures to isolate specific 
antigens from crude sonicate extracts and culture filtrate of mycobacteria. 
***** 
Generation and characterisation of T-Lymphocyte clones in BCG vacci- 
nated individuals. 
(Ongoing study, 1-97) 
The T-cell clones generated so far need to be expanded for their characterisation. 
As sufficient antigen presenting cells (APC) could not be collected from any of the 
individuals, an alternative source of APC had to be arranged. The B-lymphocytes 
of the Mononuclear cells (MNC) of each individual kept stored in liquid nitrogen was 
transformed with Epstein Bar Virus (EBV) and corresponding B-cell lines were pro- 
duced. These EBV transferred B-cells were used as APC for propagation for the T-cell 
clone. The initial experiments did not lead to successful expansion of the clones. At- 
tempts are on for propagation of the clones. 
* * * * * 
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The immunopathology of cutaneous tuberculosis 
(Ongoing study, 1992-95) 
A clinical study on cutaneous tuberculosis has been undertaken by the Centre. 
Skin biopsies from patients admitted to this study will examined for histopathological 
diagnosis and also to study the immunopathology of the disease. The methods consist 
of routine staining and immunoenzymatic staining to pick up the presence of mycobac- 
terial antigens and complement C3d using polyclonal antisera and to pick up B- and 
T- cells using monoclonal antibodies. So far, a total of 59 patients have been admitted 
to the study. 
***** 
Adrenocortical function in children wish tuberculosis meningitis and tuber- 
culous lymphadenitis. 
(Study discontinued in 1992) 
This study could not be continued in the Institute of Child Health due to frequent 
change of doctors in the specified units. 
***** 
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EPIDEMIOLOGICAL STUDIES - IN PROGRESS 
Longitudinal study of bacteriological quiescence and relapse in pulmonary 
tuberculosis under programme conditions 
(Ongoing study, 1989-93) 
An earlier cross-sectional study of the status of a retrospective cohort of smear- 
positive pulmonary tuberculosis patients in North Arcot district, showed that 31% 
of these remained bacteriologically positive even 12-36 months after starting anti- 
tuberculosis chemotherapy (1989 annual report). Among those remaining positive, 
66% had resistance to INH and 12% to rifampicin including 29% with resistance to 
more than one drug. About half the patients who had received less than 50% of 
Chemotherapy were smear negative. Since, the cohort was assembled retrospectively, 
no information on pretreatment specimens was available. Hence a longitudinal study 
was undertaken in order to have a better understanding of sputum conversion and 
relapse in relation to the amount of chemotherapy received and the pretreatment drug 
resistance status. The methodology for this study has been described in detail in the 
1989 annual report. 
Initially, three centres, namely, the District Tuberculosis Centre, Vellore and the 
Government Hospitals at Arani and Gudiyattam were selected for this study based 
on their case load. Later, the Government Sanatorium at Adukkambarai was also 
included. 
Table 1 
Study population 
Total number of patients with a positive smear 
Exclusions: 
. 
Self-reported previously treated patients 
Found to be previously treated patients on home visit 
Dead 
Outside area 
Migrated 
New cases (admitted to the study) 
No. 
2553 
985 
71 
28 
463 
147 
859 
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Any newly diagnosed patient with a positive smear, living within 20 km from these 
centres and available for follow-up was eligible for this study. Of the patients whose 
smears were positive in these four centres, 859 were eligible for admission to the study 
(Table 1). 
Of 2,090 cases that came from the study area (i.e., 20 km radius from these centres), 
only 1034 were found to be new cases. When these were visited within 10 days of their 
registration, it was found that 28 were dead and 147 had migrated. The remaining 859 
formed the study population for longitudinal follow-up (Table 1). Of these, 755 (88%) 
yielded positive cultures at intake, of which 14(2%) were not examined for sensitivity, 
588 (78%) were sensitive and 153 (20%) were resistant to one or more anti-TB drugs. 
The pattern of initial drug resistance according to the treatment received later by 
these patients is given in Table 2. 
Treatment 
SCC 
Non-SCC 
No Rx. 
Total 
No. No. Sensitive Resistant to 
Eligible Examined to SHR S H R SH HR SHR 
488 479 387 6 49 7 19 7 4 
205 201 150 5 31 4 6 3 2 
62 61 51 1 5 1 2 1 - 
755 74 1 588 12 85 12 27 11 6 
The coverages obtained for the three monthly follow-up examinations are shown in 
Table 3. 
Status 
Eligible 
Available 
Dead 
Left 
Visitors 
Table 3 
Follow-up status of new cases registered 
Month of follow-up 
3 6 9 12 
859 698 648 610 
698 648 610 574 
82 33 18 19 
74 17 20 17 
Information was available at 12 months for 574 patients and 152 were dead within 
one year of starting of treatment. Of these, 82 deaths had occurred within the first 
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5 - - - 
Table 2 
Drug sensitivity status of culture positive new cases 
3 months. This gives an early mortality of 10% among new patients who had been 
started on anti- TB treatment. Within one year, 128 (15%) patients had migrated. 
Sputum conversions: Among patients with sensitive organisms started on short 
course chemotherapy (SCC), 154 (62%) out of 247 examined had converted at 6 
months. Of the 154, 27 (18%) had relapsed at 12 months. For those started on 
standard regimen, 65 (71%) out of 91 converted at 6 months and 10 (15%) out of 65 
became sputum positive at 12 months. Among those with resistant organisms put on 
SCC, 74 (57%) out of 129 converted at 6 months and 12 (16%) of the 74 relapsed at 
12 months. Of those who were put on standard regimen, 20 (38%) out of 52 converted 
at 6 months and 4(20%) out of 20 became sputum positive at 12 months. 
***** 
Pilot study of case finding for tuberculosis in children at the community 
level 
(Ongoing study, 1990-93) 
This study was undertaken in Kadambathur panchayat union with the objective 
of developing a methodology for periodic screening of children in the community to 
identify the children likely to be suffering from tuberculosis as early as possible and 
to investigate such children. The different aspects of this methodology - training 
and assessing the health workers who could undertake this screening, examining the 
feasibility of carrying out the investigations at the community level etc. - have been 
reported earlier (annual reports 1989 and 90). A total of 6049 children of age 0-9 
years spread over 15 randomly selected panchayats of Kadambathur formed the study 
population. The intake and follow-up procedures have been reported last year (see 
annual report 1991). 
Table 1 
Status of children on periodic screening for tuberculosis 
Status on screening 
Total screened 
Abnormality attributable to TB 
Referred for: 
Clinical examination 
Investigations 
Clinical exam and 
investigation 
Only symptomatic Rx given 
Number of children at 
Intake 
6049 
757 
291 
331 
78 
786 
6 months 
6196 
795 
315 
210 
63 
1383 
12 months 
6438 
809 
154 
273 
119 
1317 
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The intake was completed in December 1991. Complete house to house screening of 
all children was undertaken at 6,12 and 18 months. The coverages obtained for different 
examinations at intake, 6 and 12 months follow up have been reported earlier. The 
status of children on periodic screening for tuberculosis upto 12 months is reported in 
Table 1. 
On screening at intake and follow-up, about 13% of children were identified as 
having abnormalities attributable to tuberculosis. Of these, 19-40% were referred for 
clinical examination only, 20-44% for investigations only and 8-15% for both. 
X-ray examination: All children screened at intake had a full plate chest x-ray 
PA view which was read by independent readers. The distribution of the types of 
shadow and their interpretation is given in Table 2. 
Table 2 
All children with clinical or radiographic abnormality were re-x-rayed after 3 months. 
The radiographic status of these children at 3 months in relation to the same at intake 
is shown in Table 3. 
At intake, the x-rays of 20 and 770 children were classified as definite and doubtful 
for tuberculosis respectively; of these, only 7 (35%) and 153 (20%) respectively were 
confirmed as having TB (definite or doubtful) at the 3rd monthly examination. 
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Status of children on periodic screening for tuberculosis 
at Intake Abnormal1 Normal Total 
Doubtful cases of 
TB on screening 
Normal/other 
non-TB abnormality 
Table 3 
Radiographic status of children at 8-months 
35 (8) 2 501 (2) 536 (10) 
15 (0) 745 (7) 760 (7) 
Total 50 (8) 1246 (9) 1296 (17) 
Clinical examination: Clinical examination was carried out for all children ac- 
cording to the algorithm and also for those with x-ray abnormalities. In addition, 
ten percent of normal children were examined as controls. Altogether 1318, 343 and 
597 children were examined clinically at intake, 6 and 12 months respectively. Of 
these 50, 19 and 42 children were suspected to have definite or doubtful TB and were 
investigated further. 
Table 4 
Validation of screening method with 
clinical examination as standard 
Screening Clinical diagnosis at Intake 
The usefulness of the algorithm to identify children having abnormalities requiring 
further investigations for tuberculosis is validated with clinical diagnosis as the stan- 
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in relation to the same at intake 
1. Abnormal includes doubltful TB or definite TB 
2. Figures in parentheses show Histopathology/Bacteriology positive cases 
It must be noted, that the definition of ‘case’ used here is very stringent. Other 
definitions such as persistent clinical or x-ray abnormality should also be considered for 
validation. It would also be of interest to study the follow-up statue of these children 
at subsequent rounds. 
Further analysis in this direction is in progress. 
***** 
Development of surveillance methodology for tuberculosis 
(Ongoing study, 1990-94) 
A long-term community-based epidemiological study has been undertaken with the 
general objective of identifying a simple, inexpensive tool for the surveillance of the 
be used can be related to infection or disease or both. The following parameters are 
being studied: 
tuberculosis situation in a community (see 1990 annual report). The parameter(s) to 
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dard (Table 4). The sensitivity and specify of screening is 70% and 60% respectively. 
Of the 760, considered to be normal by the algorithm, 15 have ben considered to be 
possible cases by the pediatrician. These had, however, been reffered for clinical ex- 
amination based on an abnormal x-ray. 
The usefulness of the algorithm is also evaluated against bacteriological or histopatho- 
logical investigations (Table 5). Ten out of the cases were identified by screening 
method. The seven cases that were missed also normal clinically and were picked 
up by abnormal x-ray. 
(a) Prevalence and trend in the age-specific infection rates in the commu- 
nity. 
(b) Age-sex specific distribution of adult bacillary cases and the trend of this 
distribution separately for prevalence and incidence cases during follow-up. 
(c) The proportion of chronic excretors among prevalence cases and their 
drug sensitivity, at each round. 
The methodology was described in detail in the previous annual reports. 
Two panchayat unions viz., Kadambathur and Tiruvelangadu were initially in- 
cluded for the survey. By December 1992, 30 panchayats (15 panchayats in each 
panchayat union) hade been covered, and a population of 69,777 has been registered. 
Coverages of 90% or more have been obtained for all examinations except tuberculin 
testing (81%) in the 15-24 years age group (Table 1). 
Table 1 
Coverages for different examination at intake 
Examination 
Symptomatic 
X-ray 
Tuberculin test 
- do - 
Sputum 
Age Group 
> 10 
> 10 
< 14 
(Years) 
15-24 
> 10 
Population 
eligible 
54414 
54414 
22357 
12986 
8000 
Population covered 
No. % 
50428 93 
49180 90 
20656 92 
10475 81 
7637 95 
Tuberculin testing among 15-24 years age group and all sputum positive cases was 
initiated in August 1991. This was done since a review of the distribution of reaction 
sizes in children below 15 years showed that there was no clear antimode in the age 
groups 0-4, 5-9 and 10-14. 
The curve for the distribution among the age group 15-24 years shows an antimode 
at 8 mm (Figure 1). Of the 403 sputum positive cases detected at intake, 298 (74%) 
were tuberculin tested. The distribution of sputum positive cases and population (24 
years or less) according to Mantoux reaction (mm) is shown in Figure 2. It is observed 
that the two curves intersect at 12 mm. All individuals with 12 mm or more induration 
are defined as positive reactors. The annual risks of infection (ARI) were estimated 
from the proportion of positive reactors and are given in Table 2. The prevalence of 
scar is low (18%). Infection rates and annual risks of infection rise sharply with age. 
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Age Scar present Scar absent 
(in years) Number Reactors Number Reactors 
examined (> 12mm) examined (> 12mm) 
No. % No. % 
<5 2277 133 5.8 4317 170 3.9 
5-9 1191 149 12.5 6143 696 11.3 
10 - 14 677 187 27.6 6051 1393 23.0 
15 - 24 1594 1030 64.6 8881 4365 49.1 
All 5739 1499 26.1 25392 6624 26.1 
1. Annual Risk of Infection 
ARI1 
(%) 
1.6 
1.6 
1.9 
3.3 
The population eligible for the selective follow up at 6 monthly intervals will be 
those with chest symptoms or x-ray abnormals in the previous survey (round) and the 
household contacts of bacteriological positive cases. The persons not x-rayed at intake 
will be examined only in the first follow up (at 6 months). Sixteen panchayats (all the 
fifteen from Kadambathur and one from Tiruvelangadu) were covered for 6 month 
12 and 18 months selective follow-ups respectively (Table 3). 
selective follow-up. Fourteen panchayats and 6 panchayats have also been covered for 
Eligi- Covered Eligi- Covered 
ble % ble % 
Table 3 
Coverage for different examinations during follow-up 
6 months 12 months 
Symptomatic 
X-ray 
sputum 
5561 90 4634 88 
5561 86 4634 87 
2652 94 2159 96 
18 month 
Eligi- Covered 
ble % 
1954 90 
1954 89 
963 94 
Two more selective follow-ups at 24 months and 30 months will precede next resur- 
vey at 3 years. 
At intake and follow up rounds, 1181 x-ray positive cases and 509 sputum positive 
cases were identified up to December 1992. The distribution of the sputum positive 
cases by smear and culture is given in Table 4. 
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Table 2 
Prevalence of infection and the estimated 
annual risks of infection 
About half the total number of cases are positive only on culture and 13% are 
Of the 509 bacteriologically positive cases, 442 were culture positive.The results of 
sensitivity to anti-TB drugs are available for 390. Of these, 47 (12%) had a history of 
previous treatment. The resistance pattern of cases to streptomycin (S), isoniazid (H) 
and rifampicin (R) at the time of detection is shown in Table 5. 
Resistance to H in persons who have not had anti-TB treatment is 10.2% and to 
The intake to the study has been temporarily discontinued in December 1992 after 
The follow-up is in progress, 
the completion of two panchayat unions due to resource constraints. 
****** 
positive only by smear. 
rifampicin is 2.6%. 
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Surveillance of individuals infected with the Human Immuno-defiency 
Virus for the development of tuberculosis 
(Ongoing study, 1989-99) 
A longitudinal cohort study was started in July 1989 with the objective of mon- 
deficiency Virus (HIV) infection. The methodology has been described in detail in the 
1990 annual report. Briefly, addresses of pereons found to be HIV positive by ELISA 
are obtained from surveillance centres. These individuals are traced and registered 
along with their contacts. After initial investigations at TRC, eligible individuals are 
selected to be followed up every six months. 
So far, addresses of 464 individuals had been received from the different centres of 
which 195 (42%) were traced and registered (Table 1). At the initial examination at 
TRC, 44 were found to be ELISA negative and another 12 to have tuberculosis. After 
excluding these 56 individuals from analysis, 139 individuals are available for Cohort 
analysis, a great majority of them being less than 30 years of age and all of them 
being HIV positive either by Western Blot (WB) or repeat ELISA. (After Western 
Blot was discontinued, repeat ELISA on an independent sample was taken to be the 
confirmatory test as a National Policy from Sept.1992). 
itoring the occurrence of tuberculosis among individuals with the Human Immuno- 
These 139 individuals have been followed up at every six month and coverages 
during the first two years of follow-up have gradually fallen from 80% at 6 months to 
about 52% at 24 months. During the 24 months period, 8 cases of tuberculosis were 
found among the 139 individuals (1 at 6 months, 3 each at 12 and 18 months and 1 at 
24 months). 
Table 1 
Not 
Source Referred trace- 
able 
STD 336 25 1 
Clinic 
Home 
Vigilance 100 1 
Others 28 9 
Died 
7 
- 
1 
8 
and Elisa Elisa positive 
registered neg WB Pos WB EQ Twice1 
78 23 55 - - 
99 13 82 1 3 
18 8 9 1 - 
195 44 136 2 3 . 
Study population 
Traced At TRC 
Total 464 261 
WB: Western Blot; EQ: Equivocal result 
1. Positive on two independent samples by ELISA 
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Chemotherapy of tuberculosis patients with HIV infection: Tuberculosis 
patients are routinely screened for HIV infection at TRC and some selected Govern- 
ment Health facilities. As a result of this screening and the follow-up of HIV infected 
individuals described above, a total of 57 cases of tuberculosis were found. 
All the 57 patients had had treatment started for TB; 30 at TRC and the others 
outside. While patients at TRC were started on a nine-month regimen containing 
Ethambutol, INH, Rifampicin and Pyrazinamide for the first two months followed by 
INH and Rifampicin for the next 7 months, other patients were treated with routine 
SCC regimens. Twenty three had completed the treatment, of which one died. For 
all the 23, the sputum became negative. Of the remaining 34 patients, 11 have died, 
11 are sputum positive and 12 sputum negative. Four patients had organism with 
multiple drug resistance and two of them have died. 
Infection among contacts: Among 119 contacts registered, 21 (18%) had HIV 
The study is in progress. 
infection at intake and 3 were infected during follow up (two within six months). 
***** 
Surveillance of tuberculosis patients for human immuno deficiency virus 
infection 
(Ongoing study, 1991-93) 
This study has been undertaken to study the proportion and trend of HIV infection 
among tuberculosis patients over time. All tuberculosis patients who reported to the 
centre (TRC), Madras, or the DTC/TB Sanatorium at Vellore, or at Pondicherry are 
screened irrespective of their bacteriological status. Extra pulmonary TB cases are also 
included. At TRC, chest symptomatics are also screened in addition to TB patients. 
Blood specimen obtained from each patient was tested by ELISA for HIV antibody. 
For specimens found to be positive, ELISA was repeated; if positive twice by ELISA, 
the specimens were tested by Western Blot (WB) for confirmation. ELISA tests were 
done at TRC and JIPMER, Pondicherry. All Western Blot tests were done at CMC, 
Vellore. 
The number screened, the number and proportion positive by ELISA and WB are 
shown in Table 1. overall, about 1% of TB patients are positive for HIV infection as 
confirmed by ELISA and Western Blot. 
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Table 1 
HIV infection in TB patients by referral centres 
ELISA positive 
Centre 
TRC,Madras 
DTC ,Vellore 
GTBS ,Vellore 
Chest Clinic, 
Pondicherry1 
GTBS, 
Pondicherry1 
Total 
Number 
screened 
4464 
112 
1952 
195 
846 
7569 
Once Twice 
99 34 
3 5 
25 39 
NA 3 
NA 6 
127 87 
western Blot 
Positive Equivocal Negative 
13 21 NA 
3 2 - 
24 5 10 
3 NA NA 
6 NA NA 
49 28 10 
1. Figures upto July 92 only; NA indicates data not available 
Detailed analysis of 2064 patients screened from Vellore is given in Tables 2 and 3. 
It can be seen that in every age group, there is a higher proportion of HIV (confirmed 
by Western Blot) among males as compared to females. Both males and females in the 
age group 20-29 years appear to be at higher risk compared to other age group (Table 
2). 
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Of twenty-seven positives confirmed by Western Blot, 23 were from those with 
pulmonary tuberculosis patients (smear or x-ray positive, - Table 3). 
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Case 
category 
New Smear 
positive 
New x-ray 
positive, 
sputum 
negative 
Sputum 
positive, 
inspite of 
adequate 
chemotherapy 
Extra 
pulmonary 
tuberculosis 
Cases on 
retreatment 
Total 
HIV infection in TB patients by case category 
Number ELSA positive Western Blot 
screened Once Twice Positive Equivocal Negative 
648 7 20 14 1 5 
772 10 15 9 3 3 
153 3 4 - 2 2 
17 1 - - - - 
474 7 5 4 1 0 
2064 28 44 27 7 10 
The study is in progress. 
***** 
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Table 3 
STATISTICAL STUDY - COMPLETED 
Stimulation Ratio : An index for lymphoproliferative response and ita sta- 
tistical properties 
(Completed study, 1992) 
Lymphoproliferative assays are carried out in several immunological investigations 
for different purposes. The proliferative response is basically measured by the ra- 
dioactive thymidine uptake and expressed as counts per minute (CPM). In the second 
IUIS/WHO report (Clin.expt.imm., 1988,74: 494), it is recommended that the results 
are best expressed as total uptake of radioactivity after subtraction of background 
values but might also be expressed as a relative proliferative response index. As early 
as 1977, Oppenheim and Billa Schecter (Manual of Clinical Immunology, Chapter 
9) suggested that the basic data should be transformed to get a normal distribution 
for proper statistical assessment because that large changes in the magnitude of 3 H- 
TdR incorporation by cultured lymphocytes with increasing duration of incubation are 
based on their exponential growth rate and small differences in growth rate become 
magnified with time and result in non-normal distribution of data. In the same year, 
Rosanna Dei and Pasqualae Urbano (Journal of Imm. Methods, 1977, 15: 169), after 
a review of 172 papers published in 1975 in three leading journals, pointed out that 
the presentation of mean CPM ± SEM (standard error of the mean) in a paper as a 
clue to an improper statistical handling of the data and considered log-transformation 
as essential for valid statistical analysis. Another disadvantage of the use of mean 
CPM ± SEM is that it renders the comparison of the results of one investigation with 
another difficult. However, untransformed data is still used for presentation of results 
and statistical analysis in several published papers. For example, the investigations of 
Fitzpatrick, E.A. et al. (3377), Brodie, C and Gelfand, E.W. (3492), Burstein, H.J. et 
al. (3687) and Miconnet, I. et al. (3706) from volume 148 of the Journal of Immunol- 
ogy (1992) provide a sample of studies in which mean CPM ± SD/SEM has been used 
for analysis. 
An index designated as Stimulation Ratio and defined as the ratio of the mean 
of logarithms of CPM in stimulated cultures to the mean of logarithms of CPM in 
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unstimulated (control) cultures is proposed in this paper as a relative lymphoprolifer- 
ative response index for general use in statistical analysis. This index is now expressed 
as a percentage, although it has been used in all earlier studies from our Centre as 
used by other investigators with a different definition, it is now called as Stimulation 
Ratio. The purpose of this paper is to provide theoretical justification for its general 
simple ratio and termed as stimulation index. Since the term stimulation index was 
use, describe its statistical properties and empirically demonstrate its properties. 
Statistical properties of Stimulation Ratio : It is expected that it will be 
normally distributed with a theoretical mean value of 100. Its value indicates the 
existence or non-existence of positive proliferative response and also provides a quan- 
titative measure for the response. The estimate also possesses the statistical property 
of consistency. 
Materials and methods : Lymphoproliferative assays were carried out on the 
lymphocytes of six healthy subjects as described by Paranjape et al. (Ind. J. Tub. 
1988, 35: 163). The stimulants consisted of 48 all possible combinations of two con- 
centrations (zero and 5 µg/ml) of PPD with two concentrations (1% and 2.5%) of each 
of 12 specimens of ascitic fluid, obtained from six tuberculous ascites patients and six 
non-tuberculous ascites patients. In addition, two sets of controls were set up for each 
subject, one set with neither ascitic fluid nor PPD and the other with PPD alone. The 
assay was set up in triplicate and assays for two specimens of ascitic fluid could not 
be set up for one subject. 
The original objective of the assays was to find out whether the tuberculous and 
non-tuberculous ascitic fluids would produce different levels of proliferative responses 
in infected healthy subjects. Statistical analysis indicated that the ascitic fluids gener- 
ally failed to produce positive proliferative response, while PPD produced significant 
responses. In view of this finding, CPMs in stimulated cultures of each subject have 
been treated, for the purpose of this analysis, as constituting two sets of replicates, the 
cultures with PPD in the stimulant as one set and all the other cultures as the second 
set. 
For calculating the index, the CPMs with 2.5% ascitic fluid are taken as values in 
stimulated cultures while CPMs in 1% of the same ascitic fluid are taken as values in 
control cultures. This procedure was adopted to empirically demonstrate the properties 
of Stimulation Ratio. Properties of another index, Reactivity Ratio, defined as the ratio 
of the mean of CPMs in stimulated cultures to the mean of CPM in control cultures 
will also be presented for comparison, as it (termed as Stimulation Index) has been 
used earlier by some investigators (Regina C.C.Dorea et al. Clin.Exp.Immunol. 1988, 
71: 26; Nelson et al., Cellular Immunology, 1987, 104: 99). Specimen values of CPM 
with corresponding values of Stimulation and Reactivity Ratios are shown in Table 1. 
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Table 1 
Specimen values of CPM and corresponding 
stimulation and reactivity ratios 
Results: The material, as described earlier and illustrated in Table 1, gave rise 
to 140 observations for each ratio. The frequency distributions of these ratios are pre- 
sented in Tables 2 and 3. 
The distribution of Stimulation Ratio is unimodal with a mean of 99 and very nearly 
symmetric around its mean. Ninety four per cent of the observations are concentrated 
in the narrow range of 89 to 112, with a standard deviation (SD) of 6.08. As for the 
Reactivity Ratio, it is spread over a wide range (22 to 271) with a mean of 101.2 and 
an SD of 43.5.. 
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Table 2 
Frequency distribution Ratio of Stimulation Ratio 
Stimulation Ratio 
(percentage) 
83 - 85 
86 - 88 
89 - 91 
92 - 94 
95 - 97 
98 - 100 
101 - 103 
104 - 106 
107 - 109 
110 - 112 
113 - 115 
116 - 123 
Total 
Frequency distribution of Reactivity Ratio 
Reactivity Ratio 
(percentage) 
22 - 49 
50 - 59 
60 - 69 
70 - 79 
80 - 89 
90 - 99 
100 - 109 
110 - 119 
120 - 129 
130 - 139 
140 - 149 
150 - 159 
160 - 169 
170 - 179 
180 - 271 
Total 
Frequency 
No. % 
3 2.1 
3 2.1 
4 2.9 
18 12.9 
22 15.7 
41 29.3 
25 17.9 
10 7.1 
4 2.9 
7 5.0 
2 1.4 
1 0.7 
140 100.0 
Table 3 
No. % 
Frequency 
11 7.9 
10 7.1 
10 7.1 
17 12.1 
11 7.9 
16 11.4 
14 10.0 
18 12.9 
9 6.4 
4 2.9 
3 2.1 
1 0.7 
2 1.4 
5 3.6 
9 6.4 
140 99.9 
105 
106 
Fig 2 Observed and expected percentage frequency 
curves for reactivity ratio 
107 
The percentage frequency curves along with expected Standardized normal curves 
are presented in Figures 1 and 2. Comparison of the observed and expected frequency 
curves in Figure 1, clearly indicates that the normal approximation for the distribution 
of Stimulation Ratio fits in nicely and is justified. In fact, the observed frequency 
curve for the Stimulation Ratio is more peaked than the expected distribution. On the 
contrary, it is seen from Figure 2 that the observed and the expected frequsncies for the 
Reactivity Ratio do not fit well and it is therefore concluded that Reactivity Ratio does 
not follow normal distribution, implying its unsuitability as relative response index. 
Although the assays are not generally carried out in such a way that the individual 
CPMs in stimulated and their corresponding control cultures could be paired, such 
a possibility can be assumed for theoretical discussion. If (yl, xl),(y2,x2), .....(yn,xn) 
represent the logarithms of CPMs of the stimulated and the corresponding control 
cultures respectively, the following two estimates of Stimulation Ratio 
where denote the respective mean values can be considered. Of these two 
estimates, T1 is biased and does not admit a simple correction for bias, where as T2 
was found to be a consistent estimator (C.R.Rao, Advanced Statistical Methods in 
Biometric Research, 1952, p 154). Hence T2 is to be preferred. 
Interpretation of Stimulation Ratio : With very weak stimulants, it has been 
empirically shown that Stimulation Ratio is normally distributed with a mean of 99. 
and an SD of 6.08. But, a hypothetical normal distribution with a mean of 100 and 
an SD of 6.08 can be considered for arriving at a criterion for positive proliferative 
response. Since larger values of Stimulation Ratio provide evidence of positive response, 
the 95th percentile of this hypothetical distribution can be chosen as the criterion for 
classification of proliferative response. Thus the response of a subject is classified as 
positive if Stimulation Ratio is higher than 110 (95th percentile) and otherwise as 
negative. 
Empirical evaluation : The Stimulation Ratio criterion for positive proliferative 
response evolved above is evaluated in a study independently carried out earlier at our 
Centre (R.S.Paranjape et al. 1988). In that investigation, the assays were carried out 
with four replicates for each specimen by different technicians following same method- 
ology with two concentrations (10 and 25 µg/ml) of PPD in a total of 105 tuberculosis 
and non-tuberculous patients. To classify the response in those patients, unpaired 
student’s t -test (with 6 degrees of freedom) was carried out for each patient to test 
the equality of means in stimulated and control cultures after logarithmic transforma- 
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1. 95th percentile of Student’s t- distribution with 6 degrees of freedom. 
It is seen from Table 4 that the two classifications agree in 197 (94%) out of 210 
comparisons. It is also important to note that 10 of the 13 disagreements are in one 
direction, i.e. with non-significant t-value but significant Stimulation Ratio. While 
ities: one is the smaller number of degrees of freedom for the t-test and the other 
is the two means compared in the t-test are correlated but the covariance could not 
be taken in to account in the test procedure. Therefore it is gratifying to note that 
Stimulation Ratio criterion has been confirmed in as high as 94% of the cases by t-test. 
it is difficult to attribute definite reasons for this finding, there can be two possibil- 
Discussion: This paper proposes Stimulation Ratio as a relative index for in- 
terpreting the results of lymphoproliferative assays. A simple criterion based on the 
value of Stimulation Ratio has been evolved to classify the proliferative response. The 
reliability of the criterion has been empirically evaluated from an independent investi- 
gation and found to be as high as 94%. Experimental data with 140 observations have 
been presented to show that Stimulation Ratio follows normal distribution, although 
experimental data did not consist of genuine replicates as some very weak stimulants 
have been used. 
Ziegler et al (Journal of Immunology, 1974, 113: 2035) reported that logarithmic 
square or cube root transformations. For the validity of t-test, the log. transforms 
of CPM in stimulated and corresponding control cultures should follow normal dis- 
of the means of log. transforms of CPM in stimulated and control cultures) also 
can follow normal distribution. In other words, if x1 and x2 follow bivariate normal 
distribution, how is the ratio, x1/x2, distributed? Fieller (1932) and Hinkley (1969) 
transformation of CPM provided better approximation to normal distribution over 
tribution. If so, the question arises whether Stimulation Ratio (defined as the ratio 
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tion of CPMs. The results of 210 such t-tests are presented in Table 4 against 
Stimulation Ratio criterion. 
derived the mathematical form of the distribution of this ratio and showed that it is 
approximately normal when the coefficient of variation of the denominator variable 
is small and tends to zero. Other conditions under which this ratio can be approxi- 
mately normally distributed have been studied in greater detail, theoretically and also 
by simulation, by Shanmugalingam (The Statistician, 1982, 31: 251). One important 
conclusion of his study is : The distribution of the ratio is symmetric about µ1 / µ2 
and approximately normal when p = C2/C1, where µl and C1 denote the mean and 
coefficient of variation of x1, µ2 and C2 the mean and coefficient of variation of x2 and 
p the coefficient of correlation between x1 and x2. It can be easily seen that, in the 
absence of any stimulation, the numerator (x1) and denominator (x2) of the Stimu- 
lation Ratio will have the same mean and same Standard deviation with correlation 
coefficient very nearly equal to unity. The values of the relevant parameters in the 
current experimental data are : µ1 = 23.5, µ2 = 23.8, C1 = 14.0, C2 = 13.7 and p 
= 0.92. Thus Shanmugalingam’s study also provides justification for our assumption 
that Stimulation Ratio follows normal distribution. 
Further, if the logic of Oppenheim and Bill Schecter is followed, the log. transforms 
of CPMs represent the growth rates of blast transformation of cells. Then either the 
difference or the ratio between the mean values of log. transforms of CPMs in stim- 
ulated and control cultures can be chosen as response index. As growth rates might 
vary from individual to individual, it is thought that the ratio of growth rates provides 
a better measure than the difference in the growth rates. 
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***** 
ELECTRONIC DATA PROCESSING 
During the year further progress was made in developing new computer programs 
for the studies, (a) Development of Surveillance methodology for tuberculosis, (b) 
(c) Short -course chemotherapy under District Tuberculosis Programme. Necessary 
modifications were carried out in previously written computer programs to suit the 
study requirements precisely. Regular support is being given by the Electronic Data 
Processing (EDP) unit to transfer files (draft texts) from IBM compatible personal 
computers to Apple Macintosh computer, in order to obtain neat laser print outputs 
of final versions of papers to be sent for publication. 
Follow-up of tuberculosis cases detected and put on treatment in surveillance study and 
Development of Surveillance methodology for tuberculosis : For this study, 
since 18-month follow-up of individuals was newly introduced during the year, com- 
puter programs were specially developed to provide the required printouts to field 
teams and to process the data on the VAX-11 computer. Data base was created for 
18-month follow-up and integrated with the main database for the Surveillance study. 
Computer printouts were provided for 9 panchayats during the year. In addition com- 
puter printouts were provided for 18 panchayats in which 6- months follow-up was due 
and 14 panchayats in which 12-month follow-up was due. 
District Tuberculosis Programme : Four new computer programs were devel- 
oped to take print outs according to performances of PHI’S. 
Payroll : System designing and system analysis were carried out during the year 
to computerise the Pay-roll of the Centre including the Epidemiology Unit. Program- 
ming support was obtained from a private software vendor to get tailor-made menu 
driven screen-oriented software developed on IBM compatible computers to meet our 
specific requirements. The administrative staff were trained to directly use the soft- 
ware to update the database and obtain the required print-outs. Paybills, payslips for 
staff members and various schedules are being prepared directly from the computer 
databases. 
For editing and printing the annual report on research activities of the Centre, 
personal computers are being used as described in the 1991 annual report. 
***** 
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LIBRARY & INFORMATION SERVICES 
The library (and Documentation Centre) of TB Research Centre has a fairly large 
collection of books and bound volumes of scientific journals on different aspects of 
and 107 foreign) scientific journals. In addition the resources of the British Council 
Library, Madras are also made use of by renewing the institutional membership facility. 
A major and significant development during the year has been the introduction of 
several new Information and Documentation Services to meet the ever growing needs 
of the scientific community of the Centre. 
I. Information and documentation services 
tuberculosis and other related subjects. The library also gets a number of (103 Indian 
(a) Current awareness service : As part of a computerised Selective Dissem- 
ination of Information (SDI) service, the library is bringing out ‘Tuberculosis Alert’ 
an in-house fortnightly publication. This contains bibliographic details of recent arti- 
cles published in Indian and foreign journals and about monograph on tuberculosis, 
mycobacterial and allied diseases. 
(b) Literature search : For scientists of the Centre, literature searches were 
conducted by utilising the MEDLARS databases available at National Information 
Centre (NIC) State Unit, Madras and CD-ROM data bases such as Medline, Bookfind, 
Book Bank etc. at British Council Library, Madras. 
(c) Library resource sharing: With a view to improve library’s resource facil- 
ities, sharing of periodicals of mutual interest has been introduced on a weekly basis 
with Vector Control Research Centre (VCRC), Pondicherry. A total of 41 periodicals 
are shared mutually. ‘Current Contents’ on Discs are also shared from VCRC. 
(d) NUCSSI, CAPS, ADONIS: The National Union Catalogue of Scientific Se- 
rials in India (NUCSSI) of Indian National Scientific Documentation Centre (INSDOC) 
has been introduced. This would facilitate the location and procurement of micro doc- 
uments (scientific articles) published in journals not subscribed by the Centre. The 
library has commenced the Contents, Abstracts and Photocopy Services (CAPS) of 
INSDOC. The ADONIS CD-ROM database of NIC, New Delhi is also made use of for 
obtaining the full-text of recent articles. 
II. Computerisation activities 
(a) The library has commenced the computerisation of the Book-Catalogue (Cur- 
rent & Retrospective) using CDS/ISIS software. 
(b) For monitoring the receipt of journals and periodicals, payment of subscriptions 
etc., computers are being used. 
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(c) A database of TRC publications and an exclusive bibliographic database on 
‘TUBERCULOSIS’ have been created and are being updated regularly. 
III.Regional Sophisticated Information Centre (RSIC) on communicable 
diseases 
The Scientific Advisory Committee (SAC) has recommended the proposal for de- 
veloping TRC as a Regional Sophisticated Information Centre on Communicable Die 
eases with emphasis on TUBERCULOSIS (RSIC-T) with assistance from WHO; The 
proposal has been approved by ICMR and is under the consideration of WHO. 
***** 
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APPENDICES 
TRAINING PROGRAMMES 
WHO Fellows 
Mr.Yin Kim Tye and Miss Tong Swee Sin, Malaysia from 26.10.92 to 6.11.92. 
Trainees 
The following underwent training in different departments as follows: 
Bacteriology 
Dr.V.P.Myneedu, Microbiologist and a technician, Lala Ram Sarup Institute of 
Tuberculosis and Allied Diseases, New Delhi, for 4 weeks from 1.1.92. 
Three M.D. ( Microbiology) and 4 M.Sc.(Microbiology) students from B.A.L.M. 
Post-graduate Institute of Basic Medical Sciences, Taramani, Madras, from 17.1.92 to 
22.1.92. 
Eighteen students of Diploma Course in Medical Laboratory Technology, Voluntary 
Health Services, Adyar, Madras, from 4.5.92 to 16.5.92. 
Cardio-Pulmonary Medicine 
Dr.Aloke Gopal Goshal, North Bengal Medical College, Siliguri, West Bengal, from 
10.4.92 to 29.4.92. 
Dr.B.Jayakrishnan, P.S.G. Institute of Medical Sciences and Research, Coimbat- 
ore, from 6.7.92 to 10.7.92. 
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Immunology 
Mr.Sanjiva Bimal, M.Sc., from Rajendra Memorial Research Institute of Medical 
Sciences, Patna, from 17.8.92 to 27.8.92. 
Pathology 
Mr.Kannadasan,Ph.D student, from Zoology department, Nandanam Arts College,. 
Madras for 1 month, from 1.3.92. 
General 
Ms.Brenda Henry and Ms.Teresa Lappanan, students from School of Social Work, 
Michigan State University, U.S.A., from 30.6.92 to 13.8.92. 
Others 
One-or two-day training programmes were arranged at the Centre for batches of 
medical students, post-graduates, nursing students and para-medical personnel, as 
given below: 
Medical students 
Kilpauk Medical College, Madras - 2 batches. 
Medical College, Calicut - 1 batch. 
Post-graduate students 
Mrs.Nalinashi, Ph.D. student from Central Leprosy Teaching 
tute, Chengalpattu. 
and Training Insti- 
Dr.Prem Kumar, M.D.(TB & CD) student from TB & ID Hospital, Visakapatnam. 
Dr.Pravin Bhat, MD(TB & CD) student from Goa Medical College, Goa. 
Thirteen M.Sc.(Microbiology) final year students from Gulbarga University, Gul- 
barga. 
Four M.Sc.(Microbiology) students from Christian Medical College, Vellore. 
M.D.(TB & CD) and DTRD students from Institute of Thoracic Medicine, Madras. 
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Nursing and para-medical students 
B.Sc.(Botany) students from Loyola College, Madras - 1 batch. 
B.Sc.(Nursing) students from Christian Medical College, Vellore -3 batches. 
B.Sc.(Nursing) students from FR 
B.Sc.(Nursing) students from Madras Medical College, Madras - 2 batches. 
Muller’s College of Nursing, Mangalore - 1 batch. 
B.Sc.(Nursing) students from Kalyani Hospital, Madras - 1 batch. 
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ICMR-WHO WORKSHOP 
A 2-day Regional workshop organised on 14th and 15th March 1992 at Puri, Orissa 
(covering Puri, West Godavari and Raichur districts), was inaugurated by Dr.S.P.Tripathy, 
DG, (ICMR). The subjects covered and the names of the speakers are given below : 
Lectures for Medical Officers 
Subject Speaker 
National Tuberculosis Programme Dr.S.P.Gupta 
Case finding - Clinical aspects Dr.I.Ranga Rao 
-d0- Bacteriological 
aspects Dr.C.N.Paramasivan 
Short course chemotherapy Dr.M.S.Jawahar 
SCC in DTP - Review of 
18 districts Dr.R.Prabhakar 
Case holding Dr.N.M.Sudarsanam 
Management of health 
services programme Dr.Jagdish Bhatia 
Documentation Mr.P.V.Krishnamurthy 
Community participation Dr.K.Thilakavathy 
Panel Discussion 
Moderator : Dr.R.Prabhakar 
Members : Dr.C.N.Paramasivan, 
Dr.N.M.Sudarsanam, 
Dr.I.Ranga Rao, 
Dr.J.Bhatia, 
Dr.N.Srinivasa Rao, 
Dr.Brahmanandam and 
Dr.R.K.Nath 
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Lectures for Lab Technicians, Treatment Organisers 
and Drug Distributors 
Subject Speaker 
Role of paramedical workers in DTP Dr.N.M.Sudarsanam 
Case finding Mr.B.N.Gopalan 
Chemotherapy in DTP Dr.M.S.Jawahar 
Case holding Dr.K.Thilakavathy 
Documentation Mr.B.Janardhanam 
Panel Discussion (KAP Questionnaire) 
Moderator : Dr.R.Prabhakar 
Members : Dr.C.N.Paramasivan, 
Mr.N.M.Sudarsanam, 
Mr.B.Janardhanam and 
Mr.A.S.L.Narayana 
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1. Mr. K. Sankaran attended a Workshop on “Common Laboratory Equipment - 
Their Theory, Practice and Maintenance” at Physiology Department, Dr.A.L.M. 
Poet-Graduate Institute of Basic Medical Sciences, Taramani, Madras, from 13- 
20, March, 1992. 
2. Mrs. Jayalakshmi Vadivel was awarded a 3-month TCTD Fellowship under 
British ODA programme for training in Nursing Education in Queen Margaret 
College, Edinburgh,U.K., from March, 1992. 
3. Dr. M.Kannapiran was awarded Ph.D. in Biochemistry by the University of 
Madras, Madras, during 1992. 
4. Dr. Daniel Herbert was awarded Ph.D. in Microbiology by the University of 
Madras, Madras, during 1992. 
5. Mr.V.Sundaram underwent a 6-week part-time computer training course on “UNIX 
and C programming" conducted by the Ramanujan Computing Centre, Anna 
University, Madras, from 28th September, 1992. 
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STAFF DEVELOPMENT PROGRAMME 
PAPERS PRESENTED AT SCIENTIFIC 
CONFERENCES 
Name of conference, 
venue and date 
International Conference 
on Respiratory Medicine, 
Apollo Hospitals, Madras, 
31 January - 1 February, 
1992 
International Academy of 
Chest Physicians & 
Surgeons (East India 
Chapter), V Zonal 
Conference on Cardio- 
Pulmonary Medicine, 
Calcutta, 15-16 
February, 1992 
-do- 
Title of paper Name of staff 
member 
Tropical eosinophilia - Dr.V.K.Vijayan 
Recent developments ( Chair person 
for a scientific session) 
Tuberculous Iympha- Dr.M.S.Jawahar 
denitis 
Tropical eosinophilia- Dr.V.K.Vijayan 
Recent advances 
Chronic airflow 
limitations 
Broncholitis 
obliterans 
XI National Congress on Clinical application -do- 
Respiratory Diseases, of flow-volume loops (Chair person for a 
Kozhikode, 19-22 scientific session) 
February, 1992 
-do- Alveolitis in victims -do- 
of toxic gas leak at 
Bhopal 
Effect of cortico- 
steroids on alveo- 
litis of chronic 
tropical eosinophilia 
-do- 
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-do- 
-do- 
-do- 
Title of paper Name of staff Name of conference, 
venue and date member 
XI National Congress on Effect of treatment Dr.V.K.Vijayan 
Kozhikode, 19-22 its subdivisions in 
Respiratory Diseases, on transfer factor and 
February, 1992 tropical eosinophilia 
Joint Annual Conference Drug resistent Dr.MS.Jawahar 
of Association of Physicians tuberculosis 
of India & Cardiological 
Society of India,Southern 
10 June 1992 
Zone, Bangalore, 
2nd National Update on Interstitial lung -do- 
Pulmonology, Kovai disease, diagnosis and (Chair person for a 
Medical Centre and management scientific session) 
Hospital Ltd., 
Coimbatore, 12-13 
September, 1992 
XIII Annual Conference Dr.K.V.Kuppurao 
of the Indian Associa- (Delegate) 
tion of Biomedical 
Scientists, Trivandrum, 
19-20 September, 1992 
First Conference and Recent advances in Dr.V.K.Vijayan 
National Update on tropical eosinophilia ( Chair person 
Allergy, Asthma and 
Applied Immunology, 
Indian Academy of 
Allergy, Bangalore, 
16-18 October, 1992 
for a scientific session) 
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Name of conference Title of paper Name of staff 
venue and date member 
X Annual Conference of Indian Modelling the spread Dr.P.Venkatesan 
Society for Medical 
Statistics and National 
Seminar on Bio-statistical 
and Demographical 
Aspects of AIDS and AIDS 
Control in India, Bombay, 1-3 
November, 1992 
of AIDS in India 
- do - 
-do- 
Analysis of spinal 
tuberculosis survival 
data : Cox and Weibull 
models with covariates 
Exploring nominal, 
ordinal and block variables 
in the path 
analysis of medical 
data 
33rd Annual Conference Use of cetylpyridinium 
of Association of chloride for the 
Microbiologists of storage of sputum samples 
India, Goa, and isolation of 
5-7 November, 1992 tubercle bacilli 
- do - Bioluminescence assay 
in mycobacteria 
4 th National Conference of 
the Respiratory Chapter of the 
Indian Academy of Paediatrics, 
Bangalore, 7-8 November,l992 
Pulmonary function testing 
in children 
First Conference of 
Tamil Nadu Science 
Congress,26-28 
November, 1992 
Survival analysis 
of censored data 
-do- 
Dr.Vanaja Kumar 
Dr.Soumya Swaminathan 
Dr.P.Venkatesan 
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Dr.N.Selvakumar 
-do- 
Name of conference, Title of Paper 
venue and date member 
47th National Con- Application of Restriction Dr.D.Sulochana 
ference on Tuber- 
Diseases, Bombay 
26-28 November, 1992 
Fragment Length Polymorphism 
of relapse and isolated positive 
cultures from tuberculous 
patients in Hong kong 
culosis & Chest (RFLP) analysis to the origins 
- do - Serial CT Scan follow up of Dr.Rajeswari 
brain tuberculoma treated with Ramachandran 
short course chemotherapy 
- do - Response of pulmonary- TB Dr.Rema Mathew 
patients with initially 
drug resistant organisms to 
treatment with short course 
chemotherapy 
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Name of staff 
PARTICIPATION BY THE CENTRE’S SCIENTISTS IN 
SYMPOSIA, WORKSHOPS AND TRAINING COURSES 
HELD AT OTHER INSTITUTIONS 
Name of the event, Title of paper Name of staff 
venue and date member 
IAL Workshop on Development of Dr.V.D.Ramanathan 
“Advances in immuno- 
Laboratory 
Techniques with 
reference to 
patient care 
in leprosy”. 
Bhilai, 5th January, 1992 
Tamilnad Hospital Ltd. 
Cheran Nagar, 
Madras, 
17 January, 1992 
CME Programme, 
Dr.A.L.M. Post-graduate 
Institute of Basic 
Medical Sciences, 
Taramani, Madras, 
1-8 February, 1992 
XI National Congress 
on Respiratory 
Diseases, Kozhikode, 
19-22 February,l992 
histological 
techniques for 
understanding 
nerve damage 
in leprosy 
Flow volume loops Dr.V.K.Vijayan 
(Guest lecture) 
Basic applied immunology Dr.Ramesh 
and immunological S.Paranjape 
techniques (4 lectures) 
Dr.A.M.Reetha 
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Name of the event, 
venue and date 
Brain Storming Meeting 
on Trends in Laboratory, 
Animal Science and 
Technology, Indian 
Perspective , Laboratory 
Animal Information 
Service Centre (LAISC), 
National Institute 
of Nutrition, Hyderabad, 
21-22 February, 1992 
CME programme, 
Tamilnad Hospital Ltd., 
Cheran Nagar, Madras, 
27 February,l992 
Indian Medical 
Association, Badagara, 
1 March,1992 
- do - 
Meeting of the Dept. 
of Bio-Technology, 
Ministry of Science & 
Technology, New Delhi, 
3 June, 1992 
Title of paper Name of staff 
member 
- Dr.Ramesh 
S.Paranjape 
Current concepts Dr.V.D.Ramanathan 
in behavioural 
immunology 
Adult respiratory Dr.V.K.Vijayan 
distress syndrome 
(Guest lecture) 
Management of -do- 
patients with 
interstitial 
lung disease 
complicated by 
diabetes mellitus 
and pulmonary 
tuberculosis 
- Dr.Alamelu Raja 
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Name of the event, 
venue and date 
Expert Committee meeting 
convened by Principal 
Secretary (Gas Relief) for 
establishing a Pulmonary 
Medicine Centre, 
Bhopal, 4-6 June, 1992 
Meeting on the development 
of new treatment for 
tuberculosis, World Health 
Organisation, Washington D.C, 
29 - 30 June,1992 
Association of Physicians 
of India Madras Chapter), 
Madras, 26 July,1992. 
Expert Commit tee meeting 
to finalise the equipment 
and staff for the proposed 
Pulmonary Medicine 
Centre at Bhopal, 
Madras, 7-8 August,1992 
Annual Meeting of the 
Association of Physicians 
of India(Madras Chapter), 
Madras, 23 August,1992 
WHO National Workshop 
on External Quality on 
Assurance Scheme Network, 
Madras Medical College, 
Madras,27-30 September,l992 
Pulmonary function 
tests in clinical 
practice 
(Guest lecture) 
- 
Internal and 
external quality 
control measures 
as practised at 
TRC in the isolation 
and identification 
of mycobacteria 
Dr.V.K.Vijayan 
(Expert member) 
Dr.T.Santha Devi 
Dr.V.K.Vijayan 
-do- 
(Expert member) 
Dr.A.M.Reetha 
Dr.C.N.Paramasivan 
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Title of paper Name of staff 
Member 
WHO/Govt. of India, 
Comprehensive Review 
Programme of National 
TB Programme, New Delhi, 
1-20 September, 1992 
Indian Association of 
Medical Microbiologists 
(Pondicherry & Tamilnadu 
Chapter), JIPMER, 
Pondicherry , 
27 September,1992 
Indian Association of 
(Pondicherry & Tamilnadu 
Chapter), JIPMER, 
Pondicherry , 
27 September, 1992 
Medical Microbiologists 
ESI Hospital, K.K.Nagar, 
Madras, 28 September, 
1992 
National Symposium, 
Heart and Lung 
Diseases - Current 
Approach, 
Institute of Integral 
Health Studies, Madras, 
3-4 October, 1962 
Indirect tests in 
the diagnosis of 
TBM 
Bronchial asthma- 
management 
(Guest lecture) 
Occupational lung 
diaeases 
Dr.R.Balambal 
Dr.K.C.Umapathy 
Mr.A.S.L.Narayana and 
Mr.V.Chandrasekaran 
Dr.N.Selvakumar 
Dr.Vanaja Kumar 
-do- 
- do - Dr.A.M.Reetha 
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Name of the event, 
venue and date 
Title of paper Name of staff 
member 
Dr. V.K.Vijayan 
Dr.C.N.Paramasivan 
Dr.Manjula Dutta 
Dr.V.Kumaraswami 
Name of the event, 
venue and date 
Indian Academy of 
Paediatrics,Coimbatore 
Branch, Coimbatore, 
15 November,l992 
Madurai Kamaraj Uni- 
versity and Merieux 
Course on Molecular 
Immunology and self 
and non-self reacti- 
vity, Madurai Kamaraj 
University, Madurai, 
16-22 November, 1992 
Seminar on Respiratory 
Medicine, Association 
of Physicians of India 
(Madras Chapter), 
Apollo Hospitals ,Madras, 
29 November,l992 
CME Programme,Child 
Trust Hospital, Madras, 
8 December, 1992 
Refresher Course on 
"Recent advances in 
Statistics for College 
Teachers", University 
of Madras, Madras, 
18-19 December, 1992 
- do - 
CME Programme, 
Apollo Hospitals, 
Madras, 20 December,1992 
Title of paper Name of staff 
member 
Simple pulmonary Dr.Soumya Swaminathan 
function testing in children 
Antigenic cross Dr.C.N.Paramasivan 
reactivity in myco- 
bacteria and its 
relevance to immune 
response in experi- 
mental system and 
in human 
Dr.V.K.Vijayan 
(Expert member) 
Recombinant DNA Dr.Sujatha 
technology and Narayanan 
its application 
in clinical 
medicine 
Statistical methods Dr.P.Venkatesan 
for analysis of (Resource person) 
cross-tabulated 
data 
Non -linear 
regression models 
-do- 
Basic techniques Dr.N.Selvakumar 
in mycobacteriology 
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LIST OF PUBLICATIONS 
Papers published 
1. Raghupati Sarma, G., Chandra Immanuel, Krishnamurthy, P.V., Rani Balasub- 
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American Review of Respiratory Diseases, 1992, 145, 36-41. 
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trieval of patients during studies on tuberculous meningitis in children. Tubercle 
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11. Manjula Datta. Tuberculosis control in the developing world : A review. In: 
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the Tuberculosis Research Centre, Madras. Progress in Clinical Neuro Sciences, 
1992,869-881. 
18. Venkatesan, P. Survival analysis of censored data. In: Mathematical, Statistics 
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19. Kuppu Rao, K.V., Vijayan, V.K., Venkatesan, P and Sankaran, R. Maximal 
respiratory flow rates in tropical eosinophilia. Bio- medicine, 1992, 12, 59-62. 
20. Rajajee, S. and Narayanan, P.R. Immunological spectrum of childhood tubercu- 
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Papers accepted for publication 
1. Selvaraj, P., Venkataprasad, N., Vijayan, V.K. and Narayanan, P.R. Altered bac- 
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lavage fluids. European Respiratory Journal. 
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dian Journal of Clinical Practice. 
9. Thomas, A., Paulin Joseph and Prabhakar, R. ‘Flu’ syndrome associated with 
other systematic manifestation with once a month rifampicin in the treatment of 
multi-bacillary leprosy. Indian Journal of Leprosy. 
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and Prabhakar, R. Bacteriological investigations for short-course chemotherapy 
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Lung Disease. 
11. Venkataraman, P., Paramasivan, C.N. and Prabhakar, R. Invitro activity of ri- 
fampicin, rifapentine and rifabutin against South Indian isolates of M.tuberculosis. 
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13. Selvakumar, N., Vanajakumar, Narayana, A.S.L., Suryanarayanan, D., Umapa- 
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In: Proceedings of the IWGMT Colloquium, International Journal of systematic 
bacteriology. Ed: Prof. Portaeles, Antwerp, Belgium. 
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J.OURNAL CLUB 
Journal club meetings were held each week, at which published scientific articles 
covering different areas of research were reviewed by staff members of various depart- 
ments in turn. A synopsis of the paper(s) to be presented and the reference details 
were circulated in advance, to facilitate better participation by the audience in the 
discussion that followed the presentation. In all, 39 such meetings were conducted 
during the year. 
LECTURES BY VISITING SCIENTISTS 
Subject Speaker 
Introduction to health 
economics Health Economist, 
Dr. Henry Glick, 
University of Pennsylvania, 
Philadelphia. 
Skin tuberculosis Prof. Patrick Yesudian, 
Prof. & Head of the Department of Dermatology, 
Madras Medical College, 
Madras. 
Cultural research methods 
and qualitative analysis 
Dr. Mitchell Weiss, 
University of Toronto, 
Canada. 
Leishmaniases and Shri K. Ilango, 
phlebotomine sandflies Assistant Zoologist, 
in India Zoological Survey of India, 
Madras. 
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DISTINGUISHED VISITORS 
1. Dr. Christopher Murray, Harvard School of Public Health, WHO 
2. Dr. Juraj Ivanyi, MRC Unit, Royal Post-graduate Medical School, 
3. Dr. Fabio Luelmo, Tuberculosis Unit, WHO, Geneva. 
4. Dr. Rose W.Pray, TB Consultant/WHO/IUAT, Geneva. 
5. Dr. Richard O’Brien, Medical Officer, WHO TB Programme, Geneva. 
6. Dr. Mitchell Weiss, Culture, Community and Health Department, 
The Clarke Institute, University of Toronto, Canada. 
7. Dr. C.P.Ramachandran, Secretary, Steering Committee, Filariasis, 
TDR, WHO, Geneva. 
8. Dr. E.A. Ottesen, Chief, Section of Clinical Parasitology, Allergy and 
Infectious Diseases, National Institute of Health, Bethesda, Maryland, 
U.S.A. 
9. Dr. Gavin Boyd, Consultant Respiratory Physician, Glasgow Royal 
Infirmaray, U.K. 
10. Dr. Stephen Burke, Senior Registrar in Respiratory Medicine, Free- 
man Hospital, New castle Upon Tyne, U.K. 
11. Dr. Astrid Brundin, University Hospital, Linkoping, Sweden. 
12. Dr. C.P.Singh, Consultant in Medicine and HOD Medicine, Dr.R.M.L. 
13. Dr. R.C. Jain, Director, Lala Ram Sarup Institute of TB and Allied 
14. Dr.(Mrs.) Shibani Bandyopdhya, Asst. Director, NICD, New Delhi. 
Steering Committee on Tuberculosis Operational Research, Geneva. 
Hammersmith Hospital, London, U.K. 
Hospital, New Delhi. 
Diseases, New Delhi. 
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STAFF MEMBERS ON ADVISORY 
COMMITTEES OF OTHER INSTITUTIONS 
Staff member Name of committee 
Dr.R.Prabhakar Temporary Adviser, WHO, Geneva. 
- do - 
- do - 
- do - 
- do - 
- do - 
- do - 
- do - 
- do - 
Fellow, International Academy of Chest 
Physicians and Surgeons of 
the American College of Chat 
Physicians, Illinois, USA. 
Editorial Board, Ceylon Medical Journal, 
Colombo, Sri Lanka 
Project Review Committee, 
Indo-US Science and Technology 
Initiative, Department of 
Science and Technology, 
Government of India. New Delhi. 
Scientific and Technical Committee for 
Vaccines against Bacterial Diseases, 
Department of Science and Technology, 
Government of India. New Delhi. 
Standing Technical Committee, 
Tuberculosis Association of India, 
New Delhi. 
Governing Body, ICMR, New Delhi. 
Project Review Committee for Tuberculosis, 
ICMR, New Delhi. 
Editorial Board, Indian Journal of Tuberculosis, 
New Delhi. 
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Staff member Name of committee 
Dr.R.Prabhakar Scientific Advisory Committee, Regional 
Medical Research Centre, ICMR, Port Blair, 
Andamas. 
- do - Planning and Research - Medical Research 
Committee of the University of Health 
Sciences, Viayawada. 
- do - Research Advisory Panel, Schieffelin Leprosy 
Research and Training Centre, Karigiri. 
- do - 
- do - 
- do - 
Planning Board, Dr. M.G.R. University of 
Medical Sciences, Madras. 
Senate, Dr.M.G.R. University of Medical 
Sciences, Madras. 
Board of Management, Vision Research 
Foundation, Madras. 
- do - Research Sub-Committee, Vision Reaearch 
Foundation, Madras. 
- do - Editorial Advisory Committee, Lung India, 
Madras. 
-do- 
- do - 
Steering Committee, Advanced Centre for 
Clinical Epidemiological Research and 
Training, Madras. 
Board of Studies - D.M.(Clinical Epidemiology) 
Course, University of Madras, Madras. 
Dr.G.Raghupati Sarma Editorial Board, 
Indian Journal of Chest Diseases and Allied Sciences, 
V.P.Chest Institute, New Delhi. 
- do - 
- do - 
Editorial Board, lndian Journal of Tuberculosis 
New Delhi. 
Research Committee, Drug Addiction Reaearch 
Centre, Madras. 
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Staff member 
DR.P.R.Narayanan 
Dr.C.N.Paramasivan 
- do - 
Dr.V.K.Viayan 
- do - 
- do - 
- do - 
- do - 
- do - 
- do - 
Name of committee 
Editorial Board, Indian Journal of Tuberculosis, 
New Delhi. 
Editorial Board, Indian Journal of Tuberculosis. 
New Delhi. 
Editorial Board, Indian Journal of Medical Microbiology, 
Madras. 
Central Crisis Group for Chemical Disasters, 
Ministry of Environment and Forest, Government 
of India, New Delhi. 
Project Advisory Committee of ICMR on Clinical 
and Broncho-alveolar Lavage studies on MIC- 
exposed people at Bhopal, Bhopal Gas Disaster 
Research Centre, ICMR, Bhopal. 
Consultant to Government of Madhya Pradesh, 
for establishing a super speciality 
hospital for pulmonary medicine at Bhopal. 
Editorial Board, 
Indian Journal of Chest Diseases and Allied Sciences,. 
V.P.Chest Institute, New Delhi. 
Member, Panel of Judges to select the best paper, 
Indian Chest Society, 1992. 
Member, Select Committee, ICMR, ‘Smt.Kamal 
Satbir Award, 1992’. 
Treasurer, International Academy of Chest 
Physicians and Surgeons (South India Chapter), 
Madras. 
- do - Assistant Editor, Lung india, Madras. 
- do - Advisory Board, Lung Sounds, Asthma and 
Bronchitis Association of India (South India 
Chapter), Madras. 
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Staff member 
Dr.V.K.Vijayan 
Dr.Padma Ramachandran 
Dr.Manjula Datta 
- do - 
- do - 
- do - 
Dr.V.Kumaraswami 
- do - 
- do - 
Dr.Soumya Swaminathan 
Dr.Manjula Datta, 
Mr.P.R.Somasundaram, 
Mr.P.V.Krishnamurthy 
Name of committee 
Respiratory Medicine Specialists panel, 
Institute of Integral Health Studies, Madras. 
State Resource Faculty, Continuing Medical 
Education in Paediatric Update, Indian Academy 
of Paediatrics, Tamil Nadu State Branch, 
Madras. 
Task Force for the National ARI Control 
Programme, Government of India, New Delhi. 
Member, Scientific Advisory 
Committee, Regional Medical Research Centre, 
Jabalpur. 
Task Force for the ARI Control Programme in 
Tamil Nadu, Government of Tamil Nadu, Madras. 
Curriculum Development Committee for Clinical 
Epidemiology, Dr.M.G.R.Univemity of Medical 
Sciences, Madras. 
WHO Expert Committee on Control of Lymphatic 
Filariasis, WHO, Geneva. 
Steering Committee, Filariasis, TDR/WHO, 
Geneva. 
Expert Advisory Panel, Parasitic Disease 
(Filariasis), WHO, Geneva. 
Member, Journal Committee, 
Indian Academy of Paediatrics (IAP), 
Journal of Practical Paediatrics, Madras. 
Steering Committee, Advanced Centre for 
Clinical Epidemiological Research and 
Training, Madras. 
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PRIZES AND AWARDS RECEIVED BY 
STAFF MEMBERS 
1. Dr. P.R. Narayanan was visiting scientist in the Laboratory of Prof.Bary R. 
Bloom, Dept. of Immunology and Microbiology, Albert Einstein College of 
Medicine, Bronx, New York, U.S.A 
2. Dr. V.K. Vijayan was awarded membership of the National Academy of Medical 
contribution for the advancement of Sciences (India) in recognition of significant 
medical sciences. 
3. Dr. C.N. Paramasivan was awarded the University of Madras/Tamil Nadu Tu- 
Lectureship in medicine for the year 1991-92. berculosis Association Endowment 
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The sad and sudden demise of Dr Menon on 30th January, 1993 is recorded with 
deep sense of sorrow. 
Dr.Menon had the distinction of being the first National Director of this Centre 
(formerly known as the Tuberculosis Chemotherapy Centre) appointed by the Indian 
Council of Medical Research, in 1965, He was endowed with an excellent clinical acu- 
men along with a rare blend of aptitude for research, qualities which made him a good 
Research Director. During his tenure as Director, the Centre continued to excel in 
clinical research in tuberculosis. The Centre initiated collaborative controlled clinic 
trials with National Tuberculosis Institute, Bangalore, during his tenure as Director 
of National Tuberculosis Institute, Bangalore. 
Earlier, he acquired rich experience in the tuberculosis control programme while in 
the Medical Service of Andhra Pradesh Government. He joined the galaxy of doyens in 
tuberculosis when he was elevated to the post of Advisor in Tuberculosis, Government 
of India, in 1969. He had served in various capacities in the World Health Organisa- 
tions as its Temporary Advisor, Short Term Consultant, etc. and was often approached 
for advice in tuberculosis control by many Government and Non-Governmental organ- 
isations. 
We pay our respectful homage to the departed soul with a prayer for it to rest in 
eternat peace. 
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